\relax 
\catcode `"\active 
\select@language{german}
\@writefile{toc}{\select@language{german}}
\@writefile{lof}{\select@language{german}}
\@writefile{lot}{\select@language{german}}
\@writefile{toc}{\contentsline {chapter}{\numberline {1}Pharmakokinetik}{8}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{lof}{\contentsline {figure}{\numberline {1.1}{\ignorespaces Pharmakokinetik/Pharmakodynamik}}{8}}
\newlabel{fig:Pharmakokinetik}{{1.1}{8}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.1}Definitionen}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakon}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneistoff}{8}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneimittel}{8}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.2}Bezeichnung von Pharmaka}{8}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.3}Pharmakokinetik/Pharmakodynamik}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakodynamik}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Elimination}{9}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.4}Biotransformation / Metabolisierung}{9}}
\@writefile{toc}{\contentsline {paragraph}{Problem}{9}}
\@writefile{toc}{\contentsline {paragraph}{L\IeC {\"o}sung}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Phase I: Funktionalisierungsreaktion}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Phase II: Konjugationsreaktion}{9}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.2}{\ignorespaces Biotransformation}}{9}}
\newlabel{fig:Biotransformation}{{1.2}{9}}
\@writefile{toc}{\contentsline {subsubsection}{Bedeutung von Arzneimittelmetabolisierungsprozessen}{9}}
\@writefile{toc}{\contentsline {subsubsection}{F\IeC {\"u}r den Fremdstoffmetabolismus wichtige Vertreter aus der Superfamilie der humanen Cytochrom P450 Monooxygenasen (CYP)}{10}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.3}{\ignorespaces Bioverf\IeC {\"u}gbarkeit}}{10}}
\newlabel{fig:Bioverfuegbarkeit}{{1.3}{10}}
\@writefile{toc}{\contentsline {subsubsection}{Mechanismen der Induktion von Cytochrom P450 Monooxygenasen}{10}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.4}{\ignorespaces Induktion von Cytochrom P450 Monooxygenasen}}{11}}
\newlabel{fig:Cytochrom2}{{1.4}{11}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele f\IeC {\"u}r Arzneimittelinteraktionen durch Enzymhemmung und -induktion}{11}}
\@writefile{toc}{\contentsline {paragraph}{Enzyminduktion}{11}}
\@writefile{toc}{\contentsline {paragraph}{Enzymhemmung}{11}}
\@writefile{toc}{\contentsline {subsubsection}{Phase II Reaktionen}{11}}
\@writefile{toc}{\contentsline {paragraph}{Glucuronosyltransferasen}{11}}
\@writefile{toc}{\contentsline {paragraph}{Glutathion-S-Transferase (GST)}{11}}
\@writefile{toc}{\contentsline {paragraph}{N-Acetyltransferase (NAT) }{11}}
\@writefile{toc}{\contentsline {paragraph}{Sulfotransferase (SULT)}{12}}
\@writefile{toc}{\contentsline {paragraph}{Methyltransferase}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Bildung aktiver oder toxischer Metabolite (Beispiele)}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.5}{\ignorespaces Bildung aktiver oder toxischer Metabolite (Beispiele)}}{12}}
\newlabel{fig:Metabolite}{{1.5}{12}}
\@writefile{toc}{\contentsline {subsubsection}{First-Pass-Effekt}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.6}{\ignorespaces First-Pass-Effekt}}{12}}
\newlabel{fig:FirstPass}{{1.6}{12}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.5}Pharmakogenetik / Genetisch bedingte Unterschiede in der Metabolisierung von Pharmaka (Beispiele)}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Phase I}{12}}
\@writefile{toc}{\contentsline {subsubsection}{Phase II}{12}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.7}{\ignorespaces Ethanol Biotransformation}}{13}}
\newlabel{fig:EthanolBiotransformation}{{1.7}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.6}Ausscheidung}{13}}
\@writefile{toc}{\contentsline {subsubsection}{renal}{13}}
\@writefile{toc}{\contentsline {subsubsection}{bil\IeC {\"a}r/intestinal}{13}}
\@writefile{toc}{\contentsline {subsubsection}{pulmonal}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.7}Elimination von Pharmaka}{13}}
\@writefile{toc}{\contentsline {subsection}{\numberline {1.0.8}Pharmakokinetische Parameter}{13}}
\@writefile{toc}{\contentsline {subsubsection}{Bioververf\IeC {\"u}gbarkeit}{13}}
\@writefile{toc}{\contentsline {paragraph}{Bei oraler gabe abh\IeC {\"a}ngig von:}{13}}
\@writefile{toc}{\contentsline {paragraph}{\IeC {\quotedblbase }area under the curve\IeC {\textquotedblright } (AUC):}{13}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.8}{\ignorespaces Elimination}}{14}}
\newlabel{fig:Elimination}{{1.8}{14}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.9}{\ignorespaces Bioverf\IeC {\"u}gbarkeit}}{14}}
\newlabel{fig:Bioverfuegbarkeit}{{1.9}{14}}
\@writefile{toc}{\contentsline {subsubsection}{Verteilungsvolumen}{14}}
\@writefile{toc}{\contentsline {subsubsection}{Clearance}{14}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.10}{\ignorespaces Clearance}}{14}}
\newlabel{fig:Clearance}{{1.10}{14}}
\@writefile{toc}{\contentsline {subsubsection}{Plasmahalbwertszeit $t_{\frac  {1}{2}}$}{14}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.11}{\ignorespaces Kinetik 0. Ordnung: (h\IeC {\"a}ufig !) Eliminationsgeschwindigkeitist proportional zur jeweiligen Plasmakonzentration, Exponentialfunktion}}{15}}
\newlabel{Fig:kinetik0}{{1.11}{15}}
\@writefile{lof}{\contentsline {figure}{\numberline {1.12}{\ignorespaces Kinetik 1. Ordung: (selten) Eliminationsgeschwindigkeit ist konstant z.B. durch S\IeC {\"a}ttigung des abbauenden Enzyms}}{15}}
\newlabel{Fig:kinetik1}{{1.12}{15}}
\@writefile{toc}{\contentsline {subsubsection}{Kinetik nach wiederholter Gabe}{15}}
\@writefile{toc}{\contentsline {paragraph}{Kumulation}{15}}
\@writefile{toc}{\contentsline {chapter}{\numberline {2}Pharmakodynamik}{16}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {2.1}Angriffsorte von Pharmaka}{16}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1.1}Fremdorganismus / Mikroorganismus}{16}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.1.2}Menschlicher / tierischer Organismus (Makroorganismus)}{16}}
\@writefile{toc}{\contentsline {subsubsection}{Extrazellul\IeC {\"a}r}{16}}
\@writefile{toc}{\contentsline {subsubsection}{Zellul\IeC {\"a}r}{16}}
\@writefile{toc}{\contentsline {section}{\numberline {2.2}Kan\IeC {\"a}le: Definiton und Funktion}{16}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.1}{\ignorespaces Kan\IeC {\"a}le der Zellmembran}}{16}}
\newlabel{fig:Kanaele}{{2.1}{16}}
\@writefile{toc}{\contentsline {subsubsection}{$Na^+$-Kan\IeC {\"a}le}{17}}
\@writefile{toc}{\contentsline {subsubsection}{$Ca^{2+}$-Kan\IeC {\"a}le}{17}}
\@writefile{toc}{\contentsline {subsubsection}{$K^+$-Kan\IeC {\"a}le}{17}}
\@writefile{toc}{\contentsline {section}{\numberline {2.3}Transporter: Definition und Funktion}{17}}
\@writefile{toc}{\contentsline {subsubsection}{Carrier}{17}}
\@writefile{toc}{\contentsline {paragraph}{$Na^+$/Neurotransmitter-Kotransporter}{17}}
\@writefile{toc}{\contentsline {paragraph}{Kation/Cl--Kotransporter}{17}}
\@writefile{toc}{\contentsline {subsubsection}{Pumpen}{17}}
\@writefile{toc}{\contentsline {paragraph}{Ionenpumpen}{17}}
\@writefile{toc}{\contentsline {paragraph}{ABC-Transporter}{17}}
\@writefile{toc}{\contentsline {section}{\numberline {2.4}Enzyme}{18}}
\@writefile{toc}{\contentsline {section}{\numberline {2.5}Rezeptor: Definition und Funktion}{18}}
\@writefile{toc}{\contentsline {section}{\numberline {2.6}Rezeptortypen}{19}}
\@writefile{toc}{\contentsline {section}{\numberline {2.7}G-Protein-gekoppelte Rezeptoren (GPCR)}{19}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.7.1}Aktivierungs-/Inaktivierungs-Zyklus}{19}}
\@writefile{toc}{\contentsline {section}{\numberline {2.8}G-Protein vermittelte Signalwege (ubiquit\IeC {\"a}r)}{19}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.8.1}G$_s$-gekoppelte Rezeptoren}{19}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{19}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.8.2}G$_{i/o}$-gekoppelte Rezeptoren}{19}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{19}}
\@writefile{toc}{\contentsline {section}{\numberline {2.9}Liganden-gesteuerte Ionenkan\IeC {\"a}le}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.10}Liganden-regulierte Enzyme}{21}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.10.1}Rezeptoren mit Tyrosinkinase-Aktivit\IeC {\"a}t (Beispiel: Insulin-Rezeptor)}{21}}
\@writefile{toc}{\contentsline {section}{\numberline {2.11}nukle\IeC {\"a}re Rezeptoren}{22}}
\@writefile{toc}{\contentsline {section}{\numberline {2.12}Pharmakon-Rezeptor-Interaktion}{22}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.2}{\ignorespaces Pharmakon-Rezeptor-Interaktion:\textit  {k1}: Geschwindigkeitskonstante der Assoziation; \textit  {k2}: Geschwindigkeitskonstante der Dissoziation im \IeC {\"A}quilibrium gilt gem\IeC {\"a}\IeC {\ss } Massenwirkungsgesetz: \textit  {KD}: \IeC {\"A}quilibrium-Dissoziations-Konstante Ma\IeC {\ss } f\IeC {\"u}r die Affinit\IeC {\"a}t KD der meisten physiologischen Rezeptoren im Bereich von: 10-9 - 10-6 M}}{22}}
\@writefile{toc}{\contentsline {section}{\numberline {2.13}Wirkungsausl\IeC {\"o}sung}{22}}
\@writefile{toc}{\contentsline {subsubsection}{Intrinsische Aktivit\IeC {\"a}t (Wirksamkeit, \IeC {\quotedblbase }efficacy\IeC {\textquotedblleft })}{22}}
\@writefile{toc}{\contentsline {subsubsection}{Konzentrations- Wirkungs-Beziehung:}{22}}
\@writefile{toc}{\contentsline {section}{\numberline {2.14}Wirksamkeit/Potenz}{22}}
\@writefile{toc}{\contentsline {subsubsection}{Potenz:}{22}}
\@writefile{toc}{\contentsline {subsubsection}{Wirksamkeit:}{22}}
\@writefile{lof}{\contentsline {figure}{\numberline {2.3}{\ignorespaces Wirkungsausl\IeC {\"o}sung: Der Effekt ist proportional der Rezeptor-Besetzung}}{22}}
\@writefile{toc}{\contentsline {section}{\numberline {2.15}Agonismus}{23}}
\@writefile{toc}{\contentsline {section}{\numberline {2.16}Antagonismus}{23}}
\@writefile{toc}{\contentsline {subsubsection}{Agonist:}{23}}
\@writefile{toc}{\contentsline {subsubsection}{Antagonist:}{23}}
\@writefile{toc}{\contentsline {subsubsection}{kompetitiver Antagonismus}{23}}
\@writefile{toc}{\contentsline {subsubsection}{nichtkompetitiver Antagonismus}{23}}
\@writefile{toc}{\contentsline {section}{\numberline {2.17}Toleranzph\IeC {\"a}nomene}{23}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.17.1}Toleranz:}{23}}
\@writefile{toc}{\contentsline {subsubsection}{pharmakokinetische Toleranz}{23}}
\@writefile{toc}{\contentsline {subsubsection}{pharmakodynamische Toleranz}{23}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.17.2}Tachyphylaxie}{23}}
\@writefile{toc}{\contentsline {section}{\numberline {2.18}Unerw\IeC {\"u}nschte Wirkungen von Pharmaka}{23}}
\@writefile{toc}{\contentsline {subsubsection}{Hauptwirkung}{23}}
\@writefile{toc}{\contentsline {subsubsection}{Nebenwirkung}{23}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkung}{24}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.1}H\IeC {\"a}ufigkeit unerw\IeC {\"u}nschter Arzneimittelwirkungen}{24}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.2}Unerw\IeC {\"u}nschte Wirkungen im Rahmen des pharmakodynamischen Wirkprofils}{24}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.3}Ursachen dosisabh\IeC {\"a}ngiger unerw\IeC {\"u}nschter Arzneimittelwirkungen}{24}}
\@writefile{toc}{\contentsline {subsubsection}{Absolute \IeC {\"U}berdosierung}{24}}
\@writefile{toc}{\contentsline {subsubsection}{Relative \IeC {\"U}berdosierung}{24}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.4}Arzneimittel-unabh\IeC {\"a}ngige Faktoren, die zu einer relativen \IeC {\"U}berdosierung f\IeC {\"u}hren}{24}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.5}Unerw\IeC {\"u}nschte Wirkungen durch Arzneimittelinteraktionen}{25}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiele}{25}}
\@writefile{toc}{\contentsline {subsection}{\numberline {2.18.6}Unerw.Wirkungen au\IeC {\ss }erhalb des pharmakodynam. Wirkprofils}{25}}
\@writefile{toc}{\contentsline {subsubsection}{Arzneimittelallergie}{25}}
\@writefile{toc}{\contentsline {subsubsection}{Pseudoallergische Reaktion}{26}}
\@writefile{toc}{\contentsline {chapter}{\numberline {3}Cholinerges System}{27}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {3.1}cholinerge und adrenerge \IeC {\"U}bertragung im peripheren efferenten Nervensystem}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.1.1}Eigenschaften des somatomotor. und autonomen Systems}{27}}
\@writefile{toc}{\contentsline {section}{\numberline {3.2}Acetylcholin}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2.1}Cholinerge Synapse}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.2.2}Acetylcholinesterase}{27}}
\@writefile{toc}{\contentsline {subsubsection}{motorische Endplatte}{27}}
\@writefile{toc}{\contentsline {subsubsection}{ZNS}{27}}
\@writefile{toc}{\contentsline {subsubsection}{sezernierte Form}{27}}
\@writefile{toc}{\contentsline {section}{\numberline {3.3}Pharmakologische Beeinflussung cholinerger Systeme}{27}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.1}Cholinerge Rezeptoren}{28}}
\@writefile{toc}{\contentsline {subsubsection}{muskarinisch}{28}}
\@writefile{toc}{\contentsline {subsubsection}{nikotinisch}{28}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.2}Agonisten / Antagonisten des nikotinischen Ach-Rezeptor}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Nikotin}{28}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{28}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakodynamik}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Cytisin / Vareniclin}{28}}
\@writefile{toc}{\contentsline {subsubsection}{Muskelrelaxantien}{29}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{29}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{29}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{29}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.3}nicht-depolarisierende Muskelrelaxantien}{29}}
\@writefile{toc}{\contentsline {paragraph}{Elimination}{29}}
\@writefile{toc}{\contentsline {paragraph}{Antidot}{29}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.3.4}depolarisiernde Muskelrelaxantien}{29}}
\@writefile{toc}{\contentsline {subsubsection}{Suxamethonium, Succinylcholin}{29}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{29}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{29}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{29}}
\@writefile{toc}{\contentsline {section}{\numberline {3.4}Agonisten / Antagonisten muskarinischer Rezeptoren antimuskarinerge Substanzen / Parasympatholytika}{29}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.1}Belladonna-Alkaloide}{29}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{30}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.2}M3-selektiv}{30}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.4.3}quartern\IeC {\"a}re Derivate}{30}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikationen f\IeC {\"u}r Parasympatholytika}{30}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen (je nach erw\IeC {\"u}nschter Wirkung)}{30}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{30}}
\@writefile{toc}{\contentsline {section}{\numberline {3.5}muskarinerge Agonisten / direkte Parasympathomimetika}{31}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikation f\IeC {\"u}r direkte Parasympathomimetika}{31}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkung}{31}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{31}}
\@writefile{toc}{\contentsline {section}{\numberline {3.6}Cholinesterase-Hemmer/indirekte Parasympathomimetika}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.1}Hydrolyse von Ach durch AchE:}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.2}Wirkung von AchE-Hemmern:}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.3}reversible AchE-Hemmer}{31}}
\@writefile{toc}{\contentsline {paragraph}{Hauptindikationen f\IeC {\"u}r ind. Parasympathomimetika}{31}}
\@writefile{toc}{\contentsline {subsection}{\numberline {3.6.4}irreversible AchE-Hemmer}{31}}
\@writefile{toc}{\contentsline {chapter}{\numberline {4}Adrenerges System}{33}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {subsubsection}{Katecholaminsynthese}{33}}
\@writefile{toc}{\contentsline {subsubsection}{Abbau von Katecholaminen}{33}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.5}adrenerge Varikosit\IeC {\"a}t}{33}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.6}Hemmer der NA-Freisetzung}{33}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.0.7}indirekte Sympathomimetika}{33}}
\@writefile{toc}{\contentsline {paragraph}{Effekt von Amphetamin auf die Noradrenalin (NA)-Freisetzung:}{34}}
\@writefile{toc}{\contentsline {section}{\numberline {4.1}adrenerge Rezeptoren}{34}}
\@writefile{lot}{\contentsline {table}{\numberline {4.1}{\ignorespaces }}{34}}
\newlabel{}{{4.1}{34}}
\@writefile{toc}{\contentsline {section}{\numberline {4.2}$\beta _2$-Adrenozeptor-Agonisten / $\beta _2$-Sympathomimetika }{34}}
\@writefile{toc}{\contentsline {paragraph}{Gabe}{34}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{34}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{34}}
\@writefile{toc}{\contentsline {section}{\numberline {4.3}$\alpha $-Adrenozeptor-Agonisten}{34}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{35}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{35}}
\@writefile{toc}{\contentsline {section}{\numberline {4.4}$\alpha _2$-Adrenozeptor-Agonisten}{35}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{35}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{35}}
\@writefile{toc}{\contentsline {section}{\numberline {4.5}$\alpha _1$-Adrenozeptor-Antagonisten}{35}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{35}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{35}}
\@writefile{toc}{\contentsline {section}{\numberline {4.6}\IeC {\textbullet }}{35}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.1}Wirkprofil}{35}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta _1$-Selektivit\IeC {\"a}t (\IeC {\quotedblbase }Kardioselektivit\IeC {\"a}t\IeC {\textquotedblleft })}{35}}
\@writefile{lot}{\contentsline {table}{\numberline {4.2}{\ignorespaces }}{36}}
\newlabel{}{{4.2}{36}}
\@writefile{toc}{\contentsline {subsubsection}{partielle agonistische Aktivit\IeC {\"a}t (PAA)}{36}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }membranstabilisierende Wirkung\IeC {\textquotedblleft }}{36}}
\@writefile{toc}{\contentsline {subsubsection}{vasodilatierende Wirkung}{36}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.2}Pharmakokinetik}{36}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.3}Kontraindikationen}{36}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.4}Wechselwirkungen}{37}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.5}Indikation}{37}}
\@writefile{toc}{\contentsline {subsection}{\numberline {4.6.6}unerw\IeC {\"u}nschte Wirkungen}{37}}
\@writefile{toc}{\contentsline {section}{\numberline {4.7}Relative Rezeptorselektivit\IeC {\"a}t von Adrenozeptor-Agonisten und -Antagonisten}{37}}
\@writefile{toc}{\contentsline {chapter}{\numberline {5}RAAS/ Diuretika}{38}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {5.1}Renin-Angiotensin-System}{38}}
\@writefile{toc}{\contentsline {section}{\numberline {5.2}Renin-Inhibitoren}{38}}
\@writefile{toc}{\contentsline {subsubsection}{Aliskiren}{38}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{38}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{38}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{38}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{38}}
\@writefile{toc}{\contentsline {section}{\numberline {5.3}ACE-Hemmer}{38}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{38}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{38}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{39}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{39}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {5.4}$AT_1$-Rezeptor-Antagonisten}{39}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{39}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {5.5}Klassen von Diuretika}{39}}
\@writefile{toc}{\contentsline {subsection}{\numberline {5.5.1}Tubuloglomerul\IeC {\"a}re Feedback-Mechanismen}{39}}
\@writefile{toc}{\contentsline {paragraph}{Regulation der GFR des Einzelnephrons}{39}}
\@writefile{toc}{\contentsline {paragraph}{Regulation der Reninfreisetzung \IeC {\"u}ber MD}{39}}
\@writefile{toc}{\contentsline {section}{\numberline {5.6}Schleifendiuretika}{40}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{40}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{40}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{40}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{40}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{40}}
\@writefile{toc}{\contentsline {section}{\numberline {5.7}Thiazide}{40}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{41}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{41}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{41}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{41}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{41}}
\@writefile{toc}{\contentsline {section}{\numberline {5.8}$K^+$-sparende Diuretika}{41}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{41}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{42}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{42}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{42}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{42}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{42}}
\@writefile{toc}{\contentsline {section}{\numberline {5.9}Mineralokortikoid-Rezeptor-Antagonisten}{42}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{42}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{42}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{42}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{42}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{42}}
\@writefile{toc}{\contentsline {paragraph}{Kontrainkdikationen}{42}}
\@writefile{toc}{\contentsline {section}{\numberline {5.10}Arterielle Hypertonie}{43}}
\@writefile{toc}{\contentsline {section}{\numberline {5.11}Therapie der Hypertonie}{43}}
\@writefile{toc}{\contentsline {subsubsection}{Ziel}{43}}
\@writefile{toc}{\contentsline {subsubsection}{nicht-medikament\IeC {\"o}s}{43}}
\@writefile{toc}{\contentsline {subsubsection}{medikament\IeC {\"o}s}{43}}
\@writefile{toc}{\contentsline {paragraph}{RR hochnormal}{43}}
\@writefile{toc}{\contentsline {paragraph}{Stadium 1}{43}}
\@writefile{toc}{\contentsline {paragraph}{Stadium 2 und 3}{43}}
\@writefile{toc}{\contentsline {subsubsection}{Stufentherapie}{43}}
\@writefile{toc}{\contentsline {paragraph}{1. Stufe}{43}}
\@writefile{toc}{\contentsline {paragraph}{2. Stufe}{43}}
\@writefile{toc}{\contentsline {paragraph}{3. Stufe}{44}}
\@writefile{toc}{\contentsline {chapter}{\numberline {6}Digitalisglykoside}{45}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {6.1}Herzinsuffizienz}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Ursachen}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Pathogenese und Klinik}{45}}
\@writefile{toc}{\contentsline {paragraph}{Kompensierte Herzinsuffizienz}{45}}
\@writefile{toc}{\contentsline {paragraph}{Dekompensierte Herzinsuffizienz}{45}}
\@writefile{toc}{\contentsline {paragraph}{bei der Diagnosestellung Unterscheidung in}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Symptome}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Klassifikation}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Prognose}{45}}
\@writefile{toc}{\contentsline {subsubsection}{Zur Behandlung der chron. Herzinsuff. eingesetzte Pharmaka}{45}}
\@writefile{toc}{\contentsline {section}{\numberline {6.2}Digitalisglykoside}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmokokinetik}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen / Wechselwirkungen}{46}}
\@writefile{toc}{\contentsline {subsubsection}{Vorgehen bei Digitalisierung}{46}}
\@writefile{toc}{\contentsline {paragraph}{langsame Digitalisierung}{47}}
\@writefile{toc}{\contentsline {paragraph}{mittelschnelle Digitalisierung}{47}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{47}}
\@writefile{toc}{\contentsline {paragraph}{Zeichen}{47}}
\@writefile{toc}{\contentsline {paragraph}{Therapie}{47}}
\@writefile{toc}{\contentsline {subsubsection}{Stellenwert der Digitalisglykoside}{47}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie der chron. Herzinsuffizienz}{47}}
\@writefile{toc}{\contentsline {paragraph}{nicht medikament\IeC {\"o}s}{47}}
\@writefile{toc}{\contentsline {paragraph}{medikament\IeC {\"o}s}{47}}
\@writefile{toc}{\contentsline {chapter}{\numberline {7}Antiarrhythmika}{48}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\@writefile{toc}{\contentsline {section}{\numberline {7.1}Mechanismen der Arrhythmieenstehung}{48}}
\@writefile{toc}{\contentsline {subsubsection}{abnorme Schrittmacheraktivit\IeC {\"a}t}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Nachdepolarisation}{48}}
\@writefile{toc}{\contentsline {paragraph}{fr\IeC {\"u}he Nachdepolarisation (EAD)}{48}}
\@writefile{toc}{\contentsline {paragraph}{sp\IeC {\"a}te Nachdepolarisation}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Blockade der Fortleitung}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Reentry}{48}}
\@writefile{toc}{\contentsline {section}{\numberline {7.2}Antiarrhythmika-Klassen (Vaughan-Williams)}{48}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.1}Klasse I-Antiarrhythmika}{48}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ia}{49}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{49}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{49}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{49}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{49}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ib}{49}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{49}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{49}}
\@writefile{toc}{\contentsline {paragraph}{Plasma-HWZ}{49}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{49}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{49}}
\@writefile{toc}{\contentsline {subsubsection}{Klasse Ic}{49}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{49}}
\@writefile{toc}{\contentsline {paragraph}{unerw. Wirkungen}{49}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{49}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.2}Klasse II-Antiarrhythmika}{50}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta $-Adrenozeptor-Blocker}{50}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.3}Klasse III-Antiarrhythmika}{50}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{50}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{50}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{50}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{50}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.4}Klasse IV-Antiarrhythmika}{50}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{50}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{50}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{50}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.5}weitere als Antiarrhythmika eingesetzte Pharmaka}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Digitalisglykoside}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Atropin}{50}}
\@writefile{toc}{\contentsline {subsubsection}{Adenosin}{50}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{50}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{50}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{50}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.2.6}weitere Kardiaka mit Wirkung auf kardiale Kan\IeC {\"a}le}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Ivabradin}{51}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{51}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{51}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{51}}
\@writefile{toc}{\contentsline {section}{\numberline {7.3}Relaxantien glatter Muskulatur}{51}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.3.1}Regulation des Tonus der glatten Muskulatur}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Gef\IeC {\"a}\IeC {\ss }e, Bronchien, Uterus, Magen-Darm-Trakt, Ableitende Harnwege}{51}}
\@writefile{toc}{\contentsline {paragraph}{Regulation \IeC {\"u}ber Rezeptoren}{51}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.3.2}NO-Donatoren}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Organische Nitrate}{51}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{51}}
\@writefile{toc}{\contentsline {paragraph}{Toleranzentwicklung bei organischen Nitraten}{51}}
\@writefile{toc}{\contentsline {paragraph}{Kardiovaskul\IeC {\"a}re Effekte von NO-Donatoren}{51}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmokokinetik}{52}}
\@writefile{toc}{\contentsline {paragraph}{Glyceroltrinitrat}{52}}
\@writefile{toc}{\contentsline {paragraph}{ISDN / ISMN}{52}}
\@writefile{toc}{\contentsline {paragraph}{Natriumnitroprussid}{52}}
\@writefile{toc}{\contentsline {paragraph}{Molsidomin}{52}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{52}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{52}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{52}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{52}}
\@writefile{toc}{\contentsline {section}{\numberline {7.4}$Ca^{2+}$-Kanalblocker}{53}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.4.1}spannungsabh\IeC {\"a}ngige $Ca^{2+}$-Kan\IeC {\"a}le}{53}}
\@writefile{toc}{\contentsline {subsubsection}{Dihydropyridine}{53}}
\@writefile{toc}{\contentsline {subsubsection}{Phenylalkylamine}{53}}
\@writefile{toc}{\contentsline {subsubsection}{Benzothiazepine}{53}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{53}}
\@writefile{toc}{\contentsline {paragraph}{kardiovaskul\IeC {\"a}re Effekte}{54}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{54}}
\@writefile{toc}{\contentsline {paragraph}{Unerw\IeC {\"u}nschte Wirkungen}{54}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{54}}
\@writefile{toc}{\contentsline {section}{\numberline {7.5}Koronare Herzkrankheit (KHK)}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.1}Pathogenese und Klinik}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Stabile Angina pectoris}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Akutes Koronarsyndrom}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Instabile Angina pectoris}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Nicht ST-Hebungsinfarkt}{54}}
\@writefile{toc}{\contentsline {subsubsection}{ST-Hebungsinfarkt}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Sonderformen}{54}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.2}Symptomatische Behandlung der Angina pectoris (A.p.)}{54}}
\@writefile{toc}{\contentsline {subsubsection}{Symptomatische Therapie der A.p. je nach Begleitarkrankungen}{55}}
\@writefile{toc}{\contentsline {subsubsection}{Prognose verbessernde Pharmakotherapie (Mortalit\IeC {\"a}tssenkung)}{55}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.5.3}Therapie des akuten Angina-pectois Anfall}{55}}
\@writefile{toc}{\contentsline {section}{\numberline {7.6}$K^+$-Kanal\IeC {\"o}ffner}{55}}
\@writefile{toc}{\contentsline {subsubsection}{ATP-abh\IeC {\"a}ngiger $K^+$-Kanal}{55}}
\@writefile{toc}{\contentsline {section}{\numberline {7.7}Phosphodiesterase(PDE)-Hemmer}{55}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.7.1}Unselektive PDE-Hemmer}{55}}
\@writefile{toc}{\contentsline {subsubsection}{Methylxanthine}{55}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{55}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{56}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{56}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{56}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{56}}
\@writefile{toc}{\contentsline {subsection}{\numberline {7.7.2}Selektive PDE-Hemmer}{56}}
\@writefile{toc}{\contentsline {subsubsection}{PDE 3-Hemmer}{56}}
\@writefile{toc}{\contentsline {subsubsection}{PDE 5-Hemmer}{56}}
\@writefile{toc}{\contentsline {paragraph}{Wirkung}{56}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{56}}
\@writefile{toc}{\contentsline {paragraph}{Unerw. Wirkungen}{56}}
\@writefile{toc}{\contentsline {paragraph}{Wechselwirkungen}{56}}
\@writefile{toc}{\contentsline {chapter}{\numberline {8}Antidiabetica}{57}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antidiabetica}{{8}{57}}
\@writefile{toc}{\contentsline {section}{\numberline {8.1}Diabetes mellitus}{57}}
\newlabel{sec:diabetes_mellitus}{{8.1}{57}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.1}Typ I Diabetes}{57}}
\newlabel{ssub:typ_i_diabetes}{{8.1.1}{57}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.2}Typ II Diabetes}{57}}
\newlabel{ssub:typ_ii_diabetes}{{8.1.2}{57}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.1.3}Sonderformen}{57}}
\newlabel{ssub:sonderformen}{{8.1.3}{57}}
\@writefile{toc}{\contentsline {section}{\numberline {8.2}Insulinsynthese/-sekretion}{57}}
\newlabel{sec:insulinsynthese_sekretion}{{8.2}{57}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.2.1}Insulin-Rezeptor}{57}}
\newlabel{ssub:insulin_rezeptor}{{8.2.1}{57}}
\@writefile{toc}{\contentsline {section}{\numberline {8.3}Insulin}{58}}
\newlabel{sec:insulin}{{8.3}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.1}Kurz-/ultrakurz-wirksame Insuline}{58}}
\newlabel{ssub:kurz_ultrakurz_wirksame_insuline}{{8.3.1}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.2}Mittellang-/lang-wirksame Insuline}{58}}
\newlabel{ssub:mittellang_lang_wirksame_insuline}{{8.3.2}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.3}Kombinations-/Mischinsuline}{58}}
\newlabel{sub:kombinations_mischinsuline}{{8.3.3}{58}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.3.4}Insulinapplikation}{58}}
\newlabel{ssub:insulinapplikation}{{8.3.4}{58}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.3.4}{58}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{58}}
\@writefile{toc}{\contentsline {section}{\numberline {8.4}Sulfonylharnstoffe}{58}}
\newlabel{sec:sulfonylharnstoffe}{{8.4}{58}}
\newlabel{subp:wirkmechanismus}{{8.4}{59}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{59}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.4.1}ATP-abh\IeC {\"a}ngiger $K^+$-Kanal}{59}}
\newlabel{ssub:atp_abh_ngiger_k_kanal}{{8.4.1}{59}}
\newlabel{subp:pharmakokinetik}{{8.4.1}{59}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{59}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.4.1}{59}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{59}}
\newlabel{subp:interaktionen}{{8.4.1}{59}}
\@writefile{toc}{\contentsline {paragraph}{Interaktionen}{59}}
\newlabel{subp:indikationen}{{8.4.1}{59}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{59}}
\newlabel{subp:kontraindikationen}{{8.4.1}{59}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{59}}
\@writefile{toc}{\contentsline {section}{\numberline {8.5}$\alpha $-Glucosidasehemmer}{59}}
\newlabel{sec:_glucosidasehemmer}{{8.5}{59}}
\newlabel{subp:wirkmechanismus}{{8.5}{59}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{59}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.5}{59}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{59}}
\newlabel{subp:konratindikationen}{{8.5}{59}}
\@writefile{toc}{\contentsline {paragraph}{Konratindikationen}{59}}
\newlabel{subp:indikation}{{8.5}{59}}
\@writefile{toc}{\contentsline {paragraph}{Indikation}{59}}
\@writefile{toc}{\contentsline {section}{\numberline {8.6}Biguanide}{59}}
\newlabel{sec:biguanide}{{8.6}{59}}
\newlabel{subp:wirkmechanismus}{{8.6}{60}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{60}}
\newlabel{subp:pharmakokinetik}{{8.6}{60}}
\@writefile{toc}{\contentsline {paragraph}{Pharmakokinetik}{60}}
\newlabel{subp:uner}{{8.6}{60}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{60}}
\newlabel{subp:kontraindikationen}{{8.6}{60}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{60}}
\newlabel{subp:indikationen}{{8.6}{60}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{60}}
\@writefile{toc}{\contentsline {section}{\numberline {8.7}Thiazolidindion-Derivate ("Glitazone")}{60}}
\newlabel{sec:thiazolidindion_derivate_}{{8.7}{60}}
\newlabel{subp:wirkmechanismus}{{8.7}{60}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{60}}
\newlabel{subp:unerw_nschte_wirkung}{{8.7}{60}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkung}{60}}
\newlabel{subp:einsatz}{{8.7}{60}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{60}}
\@writefile{toc}{\contentsline {section}{\numberline {8.8}Glucagon-like-peptide-1(GLP-1)-Agonisten}{60}}
\newlabel{sec:glucagon_like_peptide_1_glp_1_agonisten}{{8.8}{60}}
\newlabel{subp:wirkmechanismus}{{8.8}{60}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{60}}
\newlabel{subp:unerw_nschte_wirkungen}{{8.8}{61}}
\@writefile{toc}{\contentsline {paragraph}{unerw\IeC {\"u}nschte Wirkungen}{61}}
\newlabel{subp:kontraindikationen}{{8.8}{61}}
\@writefile{toc}{\contentsline {paragraph}{Kontraindikationen}{61}}
\newlabel{subp:einsatz}{{8.8}{61}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.9}Dipeptidyl-Peptidase-IV(DPP-IV)-Hemmer}{61}}
\newlabel{sec:dipeptidyl_peptidase_iv_dpp_iv_hemmer}{{8.9}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{61}}
\newlabel{par:wirkmechanismus}{{8.9}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{61}}
\newlabel{par:unerw_nschte_wirkungen}{{8.9}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{61}}
\newlabel{par:pharmakokinetik}{{8.9}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{61}}
\newlabel{par:einsatz}{{8.9}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.10}SGLT2-Inhibitoren}{61}}
\newlabel{sec:sglt2_inhibitoren}{{8.10}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{61}}
\newlabel{par:wirkmechanismus}{{8.10}{61}}
\@writefile{toc}{\contentsline {section}{\numberline {8.11}Diabets-mellitus Behandlung}{61}}
\newlabel{sec:diabets_mellitus_behandlung}{{8.11}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.11.1}Typ I Diabetes}{61}}
\newlabel{ssub:typ_i_diabetes}{{8.11.1}{61}}
\@writefile{toc}{\contentsline {subsection}{\numberline {8.11.2}Typ II Diabetes}{61}}
\newlabel{ssub:typ_ii_diabetes}{{8.11.2}{61}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakotherapie}{62}}
\newlabel{par:pharmakotherapie}{{8.11.2}{62}}
\newlabel{subp:nachteil}{{8.11.2}{62}}
\@writefile{toc}{\contentsline {paragraph}{Nachteil}{62}}
\@writefile{toc}{\contentsline {chapter}{\numberline {9}Lipidsenker}{63}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:lipidsenker}{{9}{63}}
\@writefile{toc}{\contentsline {section}{\numberline {9.1}Lipoproteinstoffwechsel}{63}}
\newlabel{sec:lipoproteinstoffwechsel}{{9.1}{63}}
\@writefile{toc}{\contentsline {section}{\numberline {9.2}Fettstoffwechselst\IeC {\"o}rung}{63}}
\newlabel{sec:fettstoffwechselst_rung}{{9.2}{63}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.1}Prim\IeC {\"a}re Hyperlipoprotein\IeC {\"a}mie}{63}}
\newlabel{ssub:prim_re_hyperlipoprotein_mie}{{9.2.1}{63}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.2}Sekund\IeC {\"a}re Hyperlipoprotein\IeC {\"a}mie}{63}}
\newlabel{ssub:sekund_re_h}{{9.2.2}{63}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.3}Bedeutung der Therapie insb. der Hypercholesterin\IeC {\"a}mie}{63}}
\newlabel{ssub:bedeutung_der_therapie_insb_der_hypercholesterin_mie}{{9.2.3}{63}}
\@writefile{toc}{\contentsline {subsection}{\numberline {9.2.4}Therapie}{64}}
\newlabel{ssub:therapie}{{9.2.4}{64}}
\@writefile{toc}{\contentsline {section}{\numberline {9.3}HMG-CoA-Reduktase-Hemmer (Statine)}{64}}
\newlabel{sec:hmg_coa_reduktase_hemmer_}{{9.3}{64}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{64}}
\newlabel{par:wirkmechanismus}{{9.3}{64}}
\newlabel{subp:pleiotrope_wirk}{{9.3}{64}}
\@writefile{toc}{\contentsline {paragraph}{Pleiotrope Wirkungen}{64}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{64}}
\newlabel{par:pharmakokinetik}{{9.3}{64}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{65}}
\newlabel{par:unerw_nschte_wirkungen}{{9.3}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{65}}
\newlabel{par:interaktionen}{{9.3}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{65}}
\newlabel{par:kontraindikationen}{{9.3}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {9.4}Cholesterol-Resorption}{65}}
\newlabel{sec:cholesterol_resorption}{{9.4}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {9.5}Anionen-Austauscher-Harze}{65}}
\newlabel{sec:anionen_austauscher_harze}{{9.5}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{65}}
\newlabel{par:wirkmechanismus}{{9.5}{65}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{65}}
\newlabel{par:unerw_nschte_wirkungen}{{9.5}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Ineraktionen}{65}}
\newlabel{par:ineraktionen}{{9.5}{65}}
\@writefile{toc}{\contentsline {section}{\numberline {9.6}Cholesterinresorptionshemmer}{65}}
\newlabel{sec:cholesterinresorptionshemmer}{{9.6}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{65}}
\newlabel{par:wirkmechanismus}{{9.6}{65}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{66}}
\newlabel{par:pharmakokinetik}{{9.6}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Indikation}{66}}
\newlabel{par:indikation}{{9.6}{66}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{66}}
\newlabel{par:unerw_nschte_wirkungen}{{9.6}{66}}
\@writefile{toc}{\contentsline {section}{\numberline {9.7}Fibrate}{66}}
\newlabel{sec:fibrate}{{9.7}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{66}}
\newlabel{par:wirkmechanismus}{{9.7}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{66}}
\newlabel{par:pharmakokinetik}{{9.7}{66}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{66}}
\newlabel{par:unerw_nschte_wirkungen}{{9.7}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{66}}
\newlabel{par:interaktionen}{{9.7}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{66}}
\newlabel{par:kontrain}{{9.7}{66}}
\@writefile{toc}{\contentsline {section}{\numberline {9.8}Nikotins\IeC {\"a}urederivate}{66}}
\newlabel{sec:nikotins_urederivate}{{9.8}{66}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{66}}
\newlabel{par:wirkmechanismus}{{9.8}{66}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{67}}
\newlabel{par:unerw_nschte_wirkungen}{{9.8}{67}}
\@writefile{toc}{\contentsline {section}{\numberline {9.9}Therapieindikationen bei Hypercholesterin\IeC {\"a}mie}{67}}
\newlabel{sec:therapieindikationen_bei_hypercholesterin_mie}{{9.9}{67}}
\@writefile{toc}{\contentsline {chapter}{\numberline {10}H\IeC {\"o}mostase, Thrombose}{68}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:h_mostase_thrombose}{{10}{68}}
\@writefile{toc}{\contentsline {section}{\numberline {10.1}Thrombozyten-Adh\IeC {\"a}sion/-Aktivierung}{68}}
\newlabel{sec:thrombozyten_adh_sion_aktivierung}{{10.1}{68}}
\@writefile{toc}{\contentsline {section}{\numberline {10.2}Fibrinbildung \IeC {\"u}ber Koagulationskaskade}{68}}
\newlabel{sec:fibrinbildung_ber_koagulationskaskade}{{10.2}{68}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.1}Antikoagulatorische Mechanismen}{68}}
\newlabel{ssub:antikoagulatorische_mechanismen}{{10.2.1}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Antithrombin III}{68}}
\newlabel{par:antithrombin_iii}{{10.2.1}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Protein C}{68}}
\newlabel{par:protein_c}{{10.2.1}{68}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.2}Pathogenese und Zusammensetzung arterieller und ven\IeC {\"o}ser Thromben}{68}}
\newlabel{ssub:pathogenese_und_zusammensetzung_arterieller_und_ven_ser_thromben}{{10.2.2}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Arterieller Thrombus (wei\IeC {\ss }er Thrombus)}{68}}
\newlabel{par:arterieller_thrombus_wei_er_thrombus_}{{10.2.2}{68}}
\@writefile{toc}{\contentsline {subsubsection}{Ven\IeC {\"o}ser Thrombus (roter Thrombus)}{68}}
\newlabel{par:ven_ser_thrombus_roter_thrombus_}{{10.2.2}{68}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.2.3}Medikament\IeC {\"o}se Beeinflussung}{68}}
\newlabel{ssub:medikament_se_beeinflussung}{{10.2.3}{68}}
\@writefile{toc}{\contentsline {section}{\numberline {10.3}Throbozxtenfunktionshemmer}{69}}
\newlabel{sec:throbozxtenfunktionshemmer}{{10.3}{69}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.1}Acetylsalicyls\IeC {\"a}ure(ASS)}{69}}
\newlabel{ssub:acetylsalicyls_ure}{{10.3.1}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{69}}
\newlabel{par:wirkmechan}{{10.3.1}{69}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{69}}
\newlabel{par:paragraph_name}{{10.3.1}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{69}}
\newlabel{par:kontraindikationen}{{10.3.1}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{69}}
\newlabel{par:einsatz}{{10.3.1}{69}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.2}Thienopyridine}{69}}
\newlabel{ssub:thienopyridine}{{10.3.2}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{69}}
\newlabel{par:wirkmechan}{{10.3.2}{69}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{69}}
\newlabel{par:unerw_nschte_wirkungen}{{10.3.2}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{69}}
\newlabel{par:einsatz}{{10.3.2}{69}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.3.3}GPIIb/IIIa(Integrin$\alpha $IIb$\beta $3)-Rezeptor-Antagonisten}{69}}
\newlabel{ssub:gpiib_iiia_integrin_iib_3_rezeptor_antagonisten}{{10.3.3}{69}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{69}}
\newlabel{par:wirkmechanismus}{{10.3.3}{69}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{70}}
\newlabel{par:unerw_nschte_wirkung}{{10.3.3}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{70}}
\newlabel{par:einsatz}{{10.3.3}{70}}
\@writefile{toc}{\contentsline {section}{\numberline {10.4}Antikoagulatien}{70}}
\newlabel{sec:section_name}{{10.4}{70}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.1}Vitamin-K-Reduktase-Hemmer (Cumarin-Derivate)}{70}}
\newlabel{ssub:vitamin_k_reduktase_hemmer_}{{10.4.1}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{70}}
\newlabel{par:wirkmechanismus}{{10.4.1}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{70}}
\newlabel{par:pharmakokinetik}{{10.4.1}{70}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{70}}
\newlabel{par:unerw_nschte_wirkungen}{{10.4.1}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{70}}
\newlabel{par:interaktionen}{{10.4.1}{70}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{71}}
\newlabel{par:kontraindikationen}{{10.4.1}{71}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{71}}
\newlabel{par:einsatz}{{10.4.1}{71}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.2}Antithrombin-III-Aktivatoren}{71}}
\newlabel{ssub:antithrombin_iii_aktivatoren}{{10.4.2}{71}}
\@writefile{toc}{\contentsline {subsubsection}{Unfraktioniertes Heparin}{71}}
\newlabel{par:unfraktioniertes_heparin}{{10.4.2}{71}}
\@writefile{toc}{\contentsline {subsubsection}{Niedermolekulares Heparin (z.B. Enoxaparin, Nadroparin, Dalteparin)}{71}}
\newlabel{par:niedermolekulares_heparin_z_b_enoxaparin_nadroparin_dalteparin_}{{10.4.2}{71}}
\@writefile{toc}{\contentsline {subsubsection}{Synthetische Pentasaccharide (z.B. Fondaparinux)}{71}}
\newlabel{par:synthetische_pentasaccharide_z_b_fondaparinux_}{{10.4.2}{71}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{71}}
\newlabel{par:unerw_nschte_wirkungen}{{10.4.2}{71}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{72}}
\newlabel{par:einsatz}{{10.4.2}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.3}Direkte Thrombin-Inhibitoren}{72}}
\newlabel{ssec:direkte_thrombin_inhibitoren}{{10.4.3}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Hirudine}{72}}
\newlabel{par:hirudine}{{10.4.3}{72}}
\@writefile{toc}{\contentsline {subsubsection}{niedermolekulare Thrombin-Inhibitoren}{72}}
\newlabel{par:niedermolekulare_thrombin_inhibitoren}{{10.4.3}{72}}
\newlabel{subp:argatroban}{{10.4.3}{72}}
\@writefile{toc}{\contentsline {paragraph}{Argatroban}{72}}
\newlabel{subp:dagibatranetexilat}{{10.4.3}{72}}
\@writefile{toc}{\contentsline {paragraph}{Dagibatranetexilat}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.4.4}Direkte Faktor Xa-Inhibitoren}{72}}
\newlabel{ssub:direkte_faktor_xa_inhib}{{10.4.4}{72}}
\@writefile{toc}{\contentsline {subsubsection}{pEinsatz}{72}}
\newlabel{par:paragraph_name}{{10.4.4}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Vorteile}{72}}
\newlabel{par:vorteile}{{10.4.4}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Nachteile}{72}}
\newlabel{par:nachteile}{{10.4.4}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Nutzen}{72}}
\newlabel{par:nutzen}{{10.4.4}{72}}
\@writefile{toc}{\contentsline {section}{\numberline {10.5}Fibrinolytika}{72}}
\newlabel{sec:fibrinolytika}{{10.5}{72}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{72}}
\newlabel{par:wirkmechanismus}{{10.5}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.5.1}Streptokinase}{72}}
\newlabel{ssub:streptokinase}{{10.5.1}{72}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.5.2}Gewebsplasminaktivator (rt-PA / Alteplase)}{73}}
\newlabel{ssub:gewebsplasminaktivator_rt_pa_alteplase_}{{10.5.2}{73}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{73}}
\newlabel{par:unerw_nschte}{{10.5.2}{73}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{73}}
\newlabel{par:einsatz}{{10.5.2}{73}}
\@writefile{toc}{\contentsline {section}{\numberline {10.6}Arterielle Thrombose, Beispiel: Akutes Koronarsyndrom}{73}}
\newlabel{sec:arterielle_thrombose_beispiel_akutes_koronarsyndrom}{{10.6}{73}}
\@writefile{toc}{\contentsline {subsection}{\numberline {10.6.1}Instabile Angina pectoris }{73}}
\newlabel{ssub:instabile_angina_pectoris_}{{10.6.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{wenn Troponin-Test positiv, aber keine ST-Streckenhebung zus\IeC {\"a}tzlich}{73}}
\newlabel{par:wenn_troponin_test_positiv_aber_keine_st_streckenhebung_zus_tzlich}{{10.6.1}{73}}
\@writefile{toc}{\contentsline {subsubsection}{bei eingetretenem Myokardinfarkt zus\IeC {\"a}tzlich}{73}}
\newlabel{par:bei_eingetretenem_myokardinfarkt_zus_tzlich}{{10.6.1}{73}}
\@writefile{toc}{\contentsline {chapter}{\numberline {11}Antiphlogistika}{74}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiphlogistika}{{11}{74}}
\@writefile{toc}{\contentsline {section}{\numberline {11.1}Nicht-steroidale Antiphlogistika / Antirheumatika (NSAID, NSAR)}{74}}
\newlabel{sec:nicht_steroidale_antiphlogistika_antirheumatika_nsaid_nsar_}{{11.1}{74}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.1}Erw\IeC {\"u}nschte Wirkqualit\IeC {\"a}ten nicht-steroidaler Antiphlogistika}{74}}
\newlabel{ssub:erw_nschte_wirkqualit_ten_nicht_steroidaler_antiphlogistika}{{11.1.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Antiphlogistische Wirkung}{74}}
\newlabel{par:antiphlogistische_wirkung}{{11.1.1}{74}}
\newlabel{subp:subparagraph_name}{{11.1.1}{74}}
\@writefile{toc}{\contentsline {paragraph}{Lokale Reaktion}{74}}
\newlabel{subp:subparagraph_name}{{11.1.1}{74}}
\@writefile{toc}{\contentsline {paragraph}{Systemische Reaktion}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Analgetische Wirkung}{74}}
\newlabel{par:analgetische_wirkung}{{11.1.1}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Antipyretische Wirkung}{74}}
\newlabel{par:antipyretische_wirkung}{{11.1.1}{74}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.2}Unerw. Wirkqualit\IeC {\"a}ten nicht-steroidaler Antiphlogistika}{74}}
\newlabel{ssub:unerw_wirkqualit_ten_nicht_steroidaler_antiphlogistika}{{11.1.2}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Gastrointestinal (v.a. COX-1)}{74}}
\newlabel{par:gastrointestinal_v_a_cox_1_}{{11.1.2}{74}}
\@writefile{toc}{\contentsline {subsubsection}{Renal (COX-1 / COX-2)}{75}}
\newlabel{par:renal_cox_1_cox_2_}{{11.1.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{ Provokation von asthmatischen Beschwerden bei Asthmatikern}{75}}
\newlabel{par:_provokation_von_asthmatischen_beschwerden_bei_asthmatikern}{{11.1.2}{75}}
\@writefile{toc}{\contentsline {subsubsection}{erh\IeC {\"o}htes Risiko f\IeC {\"u}r kardiovaskul\IeC {\"a}re Ereignisse}{75}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.3}Salicylate}{75}}
\newlabel{ssub:salicylate}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{75}}
\newlabel{par:einsatz_und_dosierung}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{75}}
\newlabel{par:pharmakokinetik}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{75}}
\newlabel{par:vergiftung}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{75}}
\newlabel{par:unerw_nschte_wirkungen}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{75}}
\newlabel{par:kontraindikationen}{{11.1.3}{75}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.4}Arylessigs\IeC {\"a}uren}{75}}
\newlabel{ssub:arylessigs_uren}{{11.1.4}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{75}}
\newlabel{par:einsatz_und_dosierung}{{11.1.4}{75}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{75}}
\newlabel{par:pharmakokinetik}{{11.1.4}{75}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{75}}
\newlabel{par:unerw_nschte_wirkungen}{{11.1.4}{75}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.5}Arylpropions\IeC {\"a}uren}{76}}
\newlabel{ssub:subsubsection_name}{{11.1.5}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{76}}
\newlabel{par:einsatz_und_dosierung}{{11.1.5}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{76}}
\newlabel{par:pharmakokinetik}{{11.1.5}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.6}Oxicame}{76}}
\newlabel{sub:oxicame}{{11.1.6}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{76}}
\newlabel{par:pharmakokinetik}{{11.1.6}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.7}Selektive COX-2 Hemmer}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkungen}{76}}
\newlabel{par:wirkungen}{{11.1.7}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{76}}
\newlabel{par:indikationen}{{11.1.7}{76}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.8}Langfristig wirksame Antirheumatika (LWAR)}{76}}
\newlabel{sub:langfristig_wirksame_antirheumatika_lwar_}{{11.1.8}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{76}}
\newlabel{par:einsatz}{{11.1.8}{76}}
\@writefile{toc}{\contentsline {subsubsection}{TNF$\alpha $/IL-1-Hemmstoffe}{76}}
\newlabel{par:tnf_alpha_il_1_hemmstoffe}{{11.1.8}{76}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{76}}
\newlabel{par:einsatz}{{11.1.8}{76}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{77}}
\newlabel{par:unerw_nschte_wirkung}{{11.1.8}{77}}
\@writefile{toc}{\contentsline {subsection}{\numberline {11.1.9}Glukokortikoide}{77}}
\newlabel{sub:glukokortikoide}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Entz\IeC {\"u}ndungshemmung durch Glukokortikoide}{77}}
\newlabel{par:entz_ndungshemmung_durch_glukokortikoide}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Immunsuppression}{77}}
\newlabel{par:immunsuppression}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik von Glukokortikoiden}{77}}
\newlabel{par:pharmakokinetik_von_glukokortikoiden}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Dosierung / Applikation von Glukokortikoiden}{77}}
\newlabel{par:dosierung_applikation_von_glukokortikoiden}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen (Dauertherapie) }{77}}
\newlabel{par:unerw_nschte_wirkungen_dauertherapie_}{{11.1.9}{77}}
\newlabel{subp:oral_lokal}{{11.1.9}{77}}
\@writefile{toc}{\contentsline {paragraph}{oral, lokal}{77}}
\newlabel{subp:inhalativ}{{11.1.9}{78}}
\@writefile{toc}{\contentsline {paragraph}{inhalativ}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Relative Kontraindikationen}{78}}
\newlabel{par:relative_kontraindikationen}{{11.1.9}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Therapeutische Anwendung von Glukokortikoiden}{78}}
\newlabel{par:therapeutische_anwendung_von_glukokortikoiden}{{11.1.9}{78}}
\newlabel{subp:substitutionstherapie}{{11.1.9}{78}}
\@writefile{toc}{\contentsline {paragraph}{Substitutionstherapie}{78}}
\newlabel{subp:_pharmakodynamische_therapie}{{11.1.9}{78}}
\@writefile{toc}{\contentsline {paragraph}{\IeC {\quotedblbase }pharmakodynamische\IeC {\textquotedblleft } Therapie}{78}}
\@writefile{toc}{\contentsline {section}{\numberline {11.2} Pharmakotherapie des Asthma bronchiale (Stufenschema)}{78}}
\newlabel{sec:_pharmakotherapie_des_asthma_bronchiale_stufenschema_}{{11.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 1}{78}}
\newlabel{par:stufe_1}{{11.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 2}{78}}
\newlabel{par:stufe_2}{{11.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 3}{78}}
\newlabel{par:stufe_3}{{11.2}{78}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 4}{79}}
\newlabel{par:stufe_4}{{11.2}{79}}
\@writefile{toc}{\contentsline {chapter}{\numberline {12}Analgetika}{80}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:analgetika}{{12}{80}}
\@writefile{toc}{\contentsline {section}{\numberline {12.1}Nozizeptoren}{80}}
\newlabel{sec:nozizeptoren}{{12.1}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Chronifizierung des Schmerzesbei pathologischen Zust\IeC {\"a}nden: Periphere Sensibilisierung }{80}}
\newlabel{par:chronifizierung_des_schmerzesbei_pathologischen_zust_nden_periphere_sensibilisierung_}{{12.1}{80}}
\@writefile{toc}{\contentsline {section}{\numberline {12.2}Nozizeptive Synapse des Hinterhorns}{80}}
\newlabel{sec:nozizeptive_synapse_des_hinterhorns}{{12.2}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Transmitter exzitatorischer nozizeptiver A$\delta $- un C-Fasern}{80}}
\newlabel{par:transmitter_exzitatorischer_nozizeptiver_a_un_c_fasern}{{12.2}{80}}
\@writefile{toc}{\contentsline {subsubsection}{Chronifizierung des Schmerzes bei pathologischen Zust\IeC {\"a}nden: Zentrale Sensibilisierung }{80}}
\@writefile{toc}{\contentsline {section}{\numberline {12.3}Deszendierendes anti-nozizeptives System}{81}}
\newlabel{sec:deszendierendes_anti_nozizeptives_system}{{12.3}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Periaqu\IeC {\"a}duktales Grau}{81}}
\newlabel{par:periaqu_duktales_grau}{{12.3}{81}}
\@writefile{toc}{\contentsline {section}{\numberline {12.4}Analgetika}{81}}
\newlabel{sec:analgetika}{{12.4}{81}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.1}antiphlogistische/saure Analgetika s. \IeC {\quotedblbase }Antiphlogistika\IeC {\textquotedblleft }}{81}}
\newlabel{sub:subsection_name}{{12.4.1}{81}}
\@writefile{toc}{\contentsline {subsubsection}{erw\IeC {\"u}nschte Wirkqualit\IeC {\"a}ten}{81}}
\newlabel{par:erw_nschte_wirkqualit_tten}{{12.4.1}{81}}
\newlabel{subp:analgetisch}{{12.4.1}{81}}
\@writefile{toc}{\contentsline {paragraph}{analgetisch}{81}}
\@writefile{toc}{\contentsline {subsubsection}{antiphlogistisch / antipyretisch}{81}}
\newlabel{par:antiphlogistisch_antipyretisch}{{12.4.1}{81}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.2}Nicht-saure Analgetika }{81}}
\newlabel{ssub:nicht_saure_analgetika_}{{12.4.2}{81}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.3}Anilinderivate}{81}}
\newlabel{sub:anilinderivate}{{12.4.3}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{81}}
\newlabel{par:einsatz_und_dosierung}{{12.4.3}{81}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{82}}
\newlabel{par:pharmakokinetik}{{12.4.3}{82}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{82}}
\newlabel{par:unerw_nschte_wirkungen}{{12.4.3}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Vergiftung}{82}}
\newlabel{par:vergiftung}{{12.4.3}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Klinik}{82}}
\newlabel{par:klinik}{{12.4.3}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{82}}
\newlabel{par:therapie}{{12.4.3}{82}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.4}Pyrazolderivate}{82}}
\newlabel{sub:pyrazolderivate}{{12.4.4}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz und Dosierung}{82}}
\newlabel{par:einsatz_und_dosierung}{{12.4.4}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{82}}
\newlabel{par:pharmakokinetik}{{12.4.4}{82}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{82}}
\newlabel{par:unerw_nschte_wirkungen}{{12.4.4}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{82}}
\newlabel{par:kontraindikationen}{{12.4.4}{82}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.4.5}narkotische / opioide Analgetika}{82}}
\newlabel{sub:narkotische_opioide_analgetika}{{12.4.5}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Opioid-Rezeptoren}{82}}
\newlabel{par:opioid_rezeptoren}{{12.4.5}{82}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkungen}{83}}
\newlabel{par:wirkungen}{{12.4.5}{83}}
\newlabel{subp:zentral}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {paragraph}{Zentral}{83}}
\newlabel{subp:peripher}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {paragraph}{Peripher}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{83}}
\newlabel{par:kontraindikationen}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {subsubsection}{wichtige unerw\IeC {\"u}nschte Wirkungen bei Dauerschmerztherapie}{83}}
\newlabel{par:wichtige_unerw_nschte_wirkungen_bei_dauerschmerztherapie}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Opiatintoxikation}{83}}
\newlabel{par:opiatintoxikation}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {subsubsection}{Reine Agonisten}{83}}
\newlabel{par:reine_agonisten}{{12.4.5}{83}}
\newlabel{subp:morphin}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {paragraph}{Morphin}{83}}
\newlabel{subp:codein}{{12.4.5}{83}}
\@writefile{toc}{\contentsline {paragraph}{Codein}{83}}
\newlabel{subp:heroin}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Heroin}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Weitere reine Agonisten}{84}}
\newlabel{subp:weitere_reine_agonisten}{{12.4.5}{84}}
\newlabel{subp:tilidin_und_naloxon}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Tilidin und Naloxon}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Weitere reine Agonisten}{84}}
\newlabel{par:weitere_reine_agonisten}{{12.4.5}{84}}
\newlabel{subp:levomethadon_methadon}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Levomethadon, Methadon}{84}}
\newlabel{subp:hydromorphon}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Hydromorphon}{84}}
\newlabel{subp:fentanyl}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Fentanyl}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Partielle Agonisten}{84}}
\newlabel{par:partielle_agonisten}{{12.4.5}{84}}
\newlabel{subp:buprenorphin}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Buprenorphin}{84}}
\newlabel{subp:pentazocin}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Pentazocin}{84}}
\@writefile{toc}{\contentsline {subsubsection}{$\mu $-Opioid Agonisten mit hemmender Wirkung auf NA/5-HT-Wiederaufnahme}{84}}
\newlabel{par:_opioid_agonisten_mit_hemmender_wirkung_auf_na_5_ht_wiederaufnahme}{{12.4.5}{84}}
\newlabel{subp:tramadol}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Tramadol}{84}}
\newlabel{subp:tapentadol}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Tapentadol}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Antagonisten}{84}}
\newlabel{par:antagonisten}{{12.4.5}{84}}
\newlabel{subp:naloxon}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Naloxon}{84}}
\newlabel{subp:methylnaltrexon}{{12.4.5}{84}}
\@writefile{toc}{\contentsline {paragraph}{Methylnaltrexon}{84}}
\@writefile{toc}{\contentsline {section}{\numberline {12.5}Toleranz, Abh\IeC {\"a}ngigkeit}{84}}
\newlabel{sec:toleranz_abh_ngigkeit}{{12.5}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Toleranz}{84}}
\newlabel{ssub:toleranz}{{12.5}{84}}
\@writefile{toc}{\contentsline {subsubsection}{Abh\IeC {\"a}ngigkeit}{85}}
\newlabel{ssub:abh_ngigkeit}{{12.5}{85}}
\@writefile{toc}{\contentsline {subsubsection}{K\IeC {\"o}rperliche Abh\IeC {\"a}ngigkeit}{85}}
\newlabel{par:k_rperliche_abh_}{{12.5}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Psychische Abh\IeC {\"a}ngigkeit}{85}}
\newlabel{par:psychische_abh_ngigkeit}{{12.5}{85}}
\newlabel{subp:reward_systeme}{{12.5}{85}}
\@writefile{toc}{\contentsline {paragraph}{Reward-Systeme}{85}}
\@writefile{toc}{\contentsline {section}{\numberline {12.6}Koanalgetika / Adjuvantien}{85}}
\newlabel{sec:koanalgetika_adjuvantien}{{12.6}{85}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.6.1}Hemmer neuronaler Natrium und Calcium Kan\IeC {\"a}le}{85}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.6.2}Nicht-selektive Noradrenalin Serotonin Wiederaufnahmehemmer }{85}}
\newlabel{sub:nicht_selektive_noradrenalin_serotonin_wiederaufnahmehemmer_}{{12.6.2}{85}}
\@writefile{toc}{\contentsline {section}{\numberline {12.7}Chronische Schmerzkrankheiten}{85}}
\newlabel{sub:chronische_schme}{{12.7}{85}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.7.1}Stufenplan der WHO f\IeC {\"u}r Behandlung chron. Tumorschmerzen}{85}}
\newlabel{sub:stufenplan_der_who_f_r_behandlung_chron_tumorschmerzen}{{12.7.1}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 1 - Nicht-opioide Analgetika}{85}}
\newlabel{par:stufe_}{{12.7.1}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 2 - Mittelstarke Opiate/Opioide + ggf. nicht-opioide Analgetika}{85}}
\newlabel{par:stufe_}{{12.7.1}{85}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 3 - Starke Opiate/Opioide + ggf. nicht-opioide Analgetika}{86}}
\newlabel{par:stufe_}{{12.7.1}{86}}
\@writefile{toc}{\contentsline {subsubsection}{Stufe 4 - Starke Opioide kontinuierlich i.v., s.c., peridural}{86}}
\newlabel{par:stufe_}{{12.7.1}{86}}
\@writefile{toc}{\contentsline {subsection}{\numberline {12.7.2}Therapieempfehlung bei chronischen Schmerzen}{86}}
\newlabel{sub:therapieempfehlung_bei_chronischen_schmerzen}{{12.7.2}{86}}
\@writefile{toc}{\contentsline {chapter}{\numberline {13}Sexualhormone}{87}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:sexualhormone}{{13}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{87}}
\newlabel{par:wirkmechanismus}{{13}{87}}
\@writefile{toc}{\contentsline {section}{\numberline {13.1}\IeC {\"O}strogene}{87}}
\newlabel{sec:_strogene}{{13.1}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Nat\IeC {\"u}rliche \IeC {\"O}strogene; geringe Bioverf\IeC {\"u}gbarkeit}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Synthetische \IeC {\"O}strogene}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{87}}
\newlabel{par:indikationen}{{13.1}{87}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{87}}
\newlabel{par:unerw_nschte_wirkung}{{13.1}{87}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{87}}
\newlabel{par:kontraindikationen}{{13.1}{87}}
\@writefile{toc}{\contentsline {section}{\numberline {13.2}Selektive Estrogen-Rezeptor Modulatoren (SERM)}{88}}
\newlabel{sec:selektive_estrogen_rezeptor_modulatoren_serm_}{{13.2}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Clomiphen}{88}}
\newlabel{par:clomiphen}{{13.2}{88}}
\@writefile{toc}{\contentsline {section}{\numberline {13.3}Anti\IeC {\"o}strogene}{88}}
\newlabel{sec:anti_strogene}{{13.3}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Fulvestrant}{88}}
\newlabel{par:fulvestrant}{{13.3}{88}}
\@writefile{toc}{\contentsline {section}{\numberline {13.4}Aromatase-Hemmer}{88}}
\newlabel{sec:aroma}{{13.4}{88}}
\@writefile{toc}{\contentsline {section}{\numberline {13.5}Gestagene}{88}}
\newlabel{sec:gestagene}{{13.5}{88}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.5.1}Synthetische Gestagene}{88}}
\newlabel{sub:synthetische_gestagene}{{13.5.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{88}}
\newlabel{subp:indikationen}{{13.5.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{88}}
\newlabel{par:unerw_nschte_wirkungen}{{13.5.1}{88}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{88}}
\newlabel{par:kontraindikationen}{{13.5.1}{88}}
\@writefile{toc}{\contentsline {section}{\numberline {13.6}Antigestagene}{89}}
\newlabel{sec:antigestagene}{{13.6}{89}}
\@writefile{toc}{\contentsline {subsubsection}{unerw. Wirkungen}{89}}
\@writefile{toc}{\contentsline {section}{\numberline {13.7}Hormonale Kontrazeptiva (Antikonzeptiva)}{89}}
\newlabel{sec:hormonale_kontrazeptiva_}{{13.7}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{89}}
\newlabel{par:wirkmechanismus}{{13.7}{89}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.7.1}Konzepte}{89}}
\newlabel{sub:konzepte}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Einstufen-Kombinationspr\IeC {\"a}parat}{89}}
\newlabel{par:einstufen_kombinationspr_parat}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Zwei-/Dreistufen-Kombinationspr\IeC {\"a}parat}{89}}
\newlabel{par:zwei_dreistufen_kombinationspr_parat}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Zweiphasen- /Sequenzpr\IeC {\"a}parat}{89}}
\newlabel{par:zweiphasen_sequenzpr_parat}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Monopr\IeC {\"a}parat (\IeC {\quotedblbase }Minipille\IeC {\textquotedblleft })}{89}}
\newlabel{par:monopr_parat_minipille_}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Depot-Gestagene}{89}}
\newlabel{par:depot_gestagene}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }postkoitale Kontrazeption\IeC {\textquotedblleft }}{89}}
\newlabel{par:_postkoitale_kontrazeption_}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{89}}
\newlabel{par:unerw_nschte_wirkungen}{{13.7.1}{89}}
\@writefile{toc}{\contentsline {subsubsection}{Gr\IeC {\"u}nde f\IeC {\"u}r \IeC {\quotedblbase }Pillenversager\IeC {\textquotedblleft }}{90}}
\newlabel{par:gr_nde_f_r_pillenversager_}{{13.7.1}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{90}}
\newlabel{par:kontraindikationen}{{13.7.1}{90}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.7.2}Sicherheit verschiedener hormonaler Kontrazeptiva (Pearl-Index)}{90}}
\newlabel{sub:sicherheit_verschiedener_hormonaler_kontrazeptiva_pearl_index_}{{13.7.2}{90}}
\@writefile{toc}{\contentsline {section}{\numberline {13.8}Androgene}{90}}
\newlabel{sec:androgene}{{13.8}{90}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.1}seynthetische Androgene}{90}}
\newlabel{sub:seynthetische_androgene}{{13.8.1}{90}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{90}}
\newlabel{par:unerw_nschte_wirkungen}{{13.8.1}{90}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.2}Androgenrezeptor-Antagonisten}{90}}
\newlabel{sub:androgenrezeptor_antagonisten}{{13.8.2}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Cyproteronacetat}{90}}
\newlabel{par:cyproteronacetat}{{13.8.2}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Flutamid}{90}}
\newlabel{par:flutamid}{{13.8.2}{90}}
\@writefile{toc}{\contentsline {subsection}{\numberline {13.8.3}5$\alpha $-Reduktasehemmer}{90}}
\newlabel{sub:5_alpha_reduktasehemmer}{{13.8.3}{90}}
\@writefile{toc}{\contentsline {subsubsection}{Finasterid}{90}}
\newlabel{par:finasterid}{{13.8.3}{90}}
\@writefile{toc}{\contentsline {chapter}{\numberline {14}Schilddr\IeC {\"u}se}{91}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:schilddr_se}{{14}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {14.1}Schildr\IeC {\"u}senhormone}{91}}
\newlabel{sec:schildr_senhormone}{{14.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Thyroxin (T$_4$)}{91}}
\newlabel{par:thyroxin_t__4_}{{14.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Trijodthyronin (T$_3$)}{91}}
\newlabel{par:trijodthyronin_t__3_}{{14.1}{91}}
\@writefile{toc}{\contentsline {subsection}{\numberline {14.1.1}Bildung}{91}}
\newlabel{sub:bildung}{{14.1.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{91}}
\newlabel{par:wirkmechanismus}{{14.1.1}{91}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{91}}
\newlabel{par:wirkung}{{14.1.1}{91}}
\@writefile{toc}{\contentsline {section}{\numberline {14.2}Therapeutische Anwendung von L-Tyroxin}{91}}
\newlabel{sec:therapeutische_anwendung_von_l_tyroxin}{{14.2}{91}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{91}}
\newlabel{par:unerw_nschte_wirkungen}{{14.2}{91}}
\@writefile{toc}{\contentsline {subsubsection}{kontraindikationen}{92}}
\newlabel{par:kontraindikationen}{{14.2}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{92}}
\newlabel{par:wechselwirkungen}{{14.2}{92}}
\@writefile{toc}{\contentsline {section}{\numberline {14.3}Thioharnstoff-Derivate / Thionamide}{92}}
\newlabel{sec:thioharnstoff_derivate_thionamide}{{14.3}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{92}}
\newlabel{par:wirkmechanismus}{{14.3}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{92}}
\newlabel{par:pharmakokinetik}{{14.3}{92}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{92}}
\newlabel{par:paragraph_name}{{14.3}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{92}}
\newlabel{par:kontraindikationen}{{14.3}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{92}}
\newlabel{par:indikationen}{{14.3}{92}}
\@writefile{toc}{\contentsline {section}{\numberline {14.4}Iodid-Ionen}{92}}
\newlabel{sec:iodid_ionen}{{14.4}{92}}
\@writefile{toc}{\contentsline {subsection}{\numberline {14.4.1}Kaliumjodid (KJ)}{92}}
\newlabel{sub:kaliumjodid_}{{14.4.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{92}}
\newlabel{par:pharmakokinetik}{{14.4.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{92}}
\newlabel{par:unerw_nschte_wirkungen}{{14.4.1}{92}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{93}}
\newlabel{par:indikationen}{{14.4.1}{93}}
\@writefile{toc}{\contentsline {section}{\numberline {14.5}Iodprophylaxe}{93}}
\newlabel{sec:iodprophylaxe}{{14.5}{93}}
\@writefile{toc}{\contentsline {chapter}{\numberline {15}Antineoplastika}{94}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antineoplastika}{{15}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Nebenwirkungen der Zytostatikatherapie}{94}}
\newlabel{par:nebenwirkungen_der_zytostatikatherapie}{{15}{94}}
\@writefile{toc}{\contentsline {section}{\numberline {15.1}Antimetabolite}{94}}
\newlabel{sec:antimetabolite}{{15.1}{94}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.1}Hemmer der Dihydrofolatreduktase}{94}}
\newlabel{sub:hemmer_der_dihydrofolatreduktase}{{15.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{94}}
\newlabel{par:wirkmechanismus}{{15.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{94}}
\newlabel{par:unerw_nschte_wirkungen}{{15.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Indikation}{94}}
\newlabel{par:indikation}{{15.1.1}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Besonderes}{94}}
\newlabel{par:besonderes}{{15.1.1}{94}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.2}Antipurine}{94}}
\newlabel{sub:antipurine}{{15.1.2}{94}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{par:wirkmechanismus}{{15.1.2}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{95}}
\newlabel{par:indikationen}{{15.1.2}{95}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{95}}
\newlabel{par:unerw_nschte_wirkun}{{15.1.2}{95}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.3}Pentostatin}{95}}
\newlabel{sub:pentostatin}{{15.1.3}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{par:wirkmechanismus}{{15.1.3}{95}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.1.4}Pyrimidin-Antimetabolite}{95}}
\newlabel{sub:pyrimidin_antimetabolite}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{par:wirkmechanismus}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{95}}
\newlabel{par:indikationen}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{ssub:wirkmechanismus}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{95}}
\newlabel{ssub:indikationen}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{95}}
\newlabel{ssub:wirkmechanismus}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{95}}
\newlabel{ssub:indikationen}{{15.1.4}{95}}
\@writefile{toc}{\contentsline {section}{\numberline {15.2}Alkylantien}{95}}
\newlabel{sec:alkylantien}{{15.2}{95}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.1}Stickstofflost-Derivate}{95}}
\newlabel{sub:stickstofflost_derivate}{{15.2.1}{95}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{96}}
\newlabel{par:pharmakokinetik}{{15.2.1}{96}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{96}}
\newlabel{par:unerw_nschte_wirkungen}{{15.2.1}{96}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{96}}
\newlabel{par:indikationen}{{15.2.1}{96}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.2}Platinfreisetzende Verbindungen}{96}}
\newlabel{sub:subsection_name}{{15.2.2}{96}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{96}}
\newlabel{ssub:wirkmechanismus}{{15.2.2}{96}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{96}}
\newlabel{ssub:unerw_nschte_wirkungen}{{15.2.2}{96}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.2.3}Nitrosoharnstoffderivate}{96}}
\newlabel{sub:nitrosoharnstoffderivate}{{15.2.3}{96}}
\@writefile{toc}{\contentsline {subsubsection}{Besonderheiten}{96}}
\newlabel{ssub:besonderheiten}{{15.2.3}{96}}
\@writefile{toc}{\contentsline {subsubsection}{unterw\IeC {\"u}nschte Wirkungen}{96}}
\newlabel{ssub:unterw_nschte_wirkungen}{{15.2.3}{96}}
\@writefile{toc}{\contentsline {section}{\numberline {15.3}Zytostatisch wirksame Antibiotika}{96}}
\newlabel{sec:zytostatisch_wirksame_antibiotika}{{15.3}{96}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.3.1}Anthracycline}{96}}
\newlabel{sub:anthracycline}{{15.3.1}{96}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{96}}
\newlabel{ssub:wirkmechanismus}{{15.3.1}{96}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkung}{96}}
\newlabel{ssub:unerw_nschte_wirk}{{15.3.1}{96}}
\@writefile{toc}{\contentsline {section}{\numberline {15.4}Mitosehemmstoffe}{97}}
\newlabel{sec:mitosehemmstoffe}{{15.4}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.4.1}Vinca-Alkaloide}{97}}
\newlabel{sub:vinca_al}{{15.4.1}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{97}}
\newlabel{par:wirkmechanismus}{{15.4.1}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.4.2}Taxane}{97}}
\newlabel{sub:taxane}{{15.4.2}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{97}}
\newlabel{ssub:wirkmechanismus}{{15.4.2}{97}}
\@writefile{toc}{\contentsline {section}{\numberline {15.5}Inhibitoren der Topoisomerase}{97}}
\newlabel{sec:inhibitoren_der_topoisomerase}{{15.5}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Topotectan}{97}}
\newlabel{ssub:topotectan}{{15.5}{97}}
\@writefile{toc}{\contentsline {subsubsection}{Etoposid}{97}}
\newlabel{ssub:etoposid}{{15.5}{97}}
\@writefile{toc}{\contentsline {section}{\numberline {15.6}Hormontherapie}{97}}
\newlabel{sec:hormontherapie}{{15.6}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.6.1}Hormon-sensitives Mammakarzinom }{97}}
\newlabel{sub:hormon_sensitives_mammakarzinom_}{{15.6.1}{97}}
\@writefile{toc}{\contentsline {subsection}{\numberline {15.6.2}Hormonsensitives Prostatakarzinom}{97}}
\newlabel{sub:hormonsensitives_prostatakarzinom}{{15.6.2}{97}}
\@writefile{toc}{\contentsline {section}{\numberline {15.7}Tyrosinkinase-Hemmer}{98}}
\newlabel{sec:tyrosinkinase_hemmer}{{15.7}{98}}
\@writefile{toc}{\contentsline {section}{\numberline {15.8}Protease-Inhibitor}{98}}
\newlabel{sec:protease_inhibitor}{{15.8}{98}}
\@writefile{toc}{\contentsline {section}{\numberline {15.9}Antik\IeC {\"o}rper}{98}}
\newlabel{sec:antik_rper}{{15.9}{98}}
\@writefile{toc}{\contentsline {section}{\numberline {15.10}Resistenzentwicklungen}{98}}
\newlabel{sec:resistenzentwicklungen}{{15.10}{98}}
\@writefile{toc}{\contentsline {chapter}{\numberline {16}Toxikologie}{99}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:toxikologie}{{16}{99}}
\@writefile{toc}{\contentsline {section}{\numberline {16.1}Behandlungsprinzipien akuter Intoxikationen}{99}}
\newlabel{sec:behandlungsprinzipien_akuter_intoxikationen}{{16.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Hemmung von Resorption}{99}}
\newlabel{ssub:hemmung_von_resorption}{{16.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Induziertes Erbrechen nie bei}{99}}
\newlabel{ssub:induziertes_erbrechen_nie_bei}{{16.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Beschleunighte Giftelimination}{99}}
\newlabel{ssub:beschleunighte_giftelimination}{{16.1}{99}}
\@writefile{toc}{\contentsline {subsubsection}{Antidote}{99}}
\newlabel{ssub:antidote}{{16.1}{99}}
\@writefile{toc}{\contentsline {section}{\numberline {16.2}Gase}{100}}
\newlabel{sec:gase}{{16.2}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.1}Reizgase}{100}}
\newlabel{sub:reizgase}{{16.2.1}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Toxisches Lungen\IeC {\"o}dem}{100}}
\newlabel{ssub:toxisches_lungen_dem}{{16.2.1}{100}}
\newlabel{par:therapie}{{16.2.1}{100}}
\@writefile{toc}{\contentsline {paragraph}{Therapie}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.2}Systemisch wirkende Gase}{100}}
\newlabel{sub:systemisch_wirkende_gase}{{16.2.2}{100}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.3}Meth\IeC {\"a}moglobinbildner}{100}}
\newlabel{sub:meth_moglobinbildner}{{16.2.3}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Mechanismus}{100}}
\newlabel{ssub:mechanismus}{{16.2.3}{100}}
\@writefile{toc}{\contentsline {subsubsection}{Klinik}{101}}
\newlabel{ssub:klinik}{{16.2.3}{101}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{101}}
\newlabel{ssub:therapie}{{16.2.3}{101}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.4}Metalle}{101}}
\newlabel{sub:metalle}{{16.2.4}{101}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.5}S\IeC {\"a}uren, Laugen, Tenside, L\IeC {\"o}sungsmittel}{102}}
\newlabel{sub:s_uren_laugen_tenside_l_sungsmittel}{{16.2.5}{102}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.6}Halogenierte aromatische Kohlenwasserstoffe: Polychlorierte Dibenzodioxine und -furane}{102}}
\newlabel{sub:halogenierte_aromatische_kohlenwasserstoffe_polychlorierte_dibenzodioxine_und_furane}{{16.2.6}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Entstehung}{102}}
\newlabel{ssub:entstehung}{{16.2.6}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Kinetik}{102}}
\newlabel{ssub:kinetik}{{16.2.6}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{102}}
\newlabel{ssub:wirkung}{{16.2.6}{102}}
\@writefile{toc}{\contentsline {subsubsection}{Toxische Wirkung}{102}}
\newlabel{ssub:toxische_wirkung}{{16.2.6}{102}}
\@writefile{lof}{\contentsline {figure}{\numberline {16.1}{\ignorespaces Blutethanol Berechnung VD$_{M\mathaccentV {ddot}07F{a}nner}$ = 0,7 VD$_{Frauen}$ = 0,6}}{103}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.7}Bakterielle Toxine}{103}}
\newlabel{sub:bakterielle_toxine}{{16.2.7}{103}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.8}Alkohole (Methanol, Ethanol)}{103}}
\newlabel{sub:alkohole_}{{16.2.8}{103}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{103}}
\newlabel{ssub:pharmakokinetik}{{16.2.8}{103}}
\@writefile{toc}{\contentsline {subsubsection}{akute Effekte Ethanol}{103}}
\newlabel{ssub:akute_effekte_ethanol}{{16.2.8}{103}}
\@writefile{toc}{\contentsline {subsubsection}{chronische Effekte Ethanol}{104}}
\newlabel{ssub:chronische_effekte_ethanol}{{16.2.8}{104}}
\@writefile{toc}{\contentsline {subsubsection}{akute Effekte Methanol}{104}}
\newlabel{ssub:akute_effekte_methanol}{{16.2.8}{104}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.2.9}Tabakrauch}{104}}
\newlabel{sub:tabakrauch}{{16.2.9}{104}}
\@writefile{toc}{\contentsline {subsubsection}{Tabakrauch}{104}}
\newlabel{ssub:subsubsection_name}{{16.2.9}{104}}
\@writefile{toc}{\contentsline {subsubsection}{akute Wirkung v.a. Nikotin}{104}}
\newlabel{ssub:akute_wirkung_v_a_nikotin}{{16.2.9}{104}}
\@writefile{toc}{\contentsline {subsubsection}{chronische Wirkung}{104}}
\newlabel{ssub:chronische_wirkung}{{16.2.9}{104}}
\@writefile{toc}{\contentsline {section}{\numberline {16.3}Krebserzeugende Stoffe}{104}}
\newlabel{sec:krebserzeugende_stoffe}{{16.3}{104}}
\@writefile{toc}{\contentsline {subsubsection}{Polycyclische aromatische Kohlenwasserstoffe: Benzo(a)pyren, Benzo(a)athracen}{104}}
\newlabel{ssub:polycyclische_aromatische_kohlenwasserstoffe_benzo}{{16.3}{104}}
\@writefile{toc}{\contentsline {subsubsection}{Entstehung}{104}}
\newlabel{ssub:entstehung}{{16.3}{104}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{104}}
\newlabel{ssub:pharmakokinetik}{{16.3}{104}}
\@writefile{toc}{\contentsline {subsubsection}{Chronische Toxizit\IeC {\"a}t}{105}}
\newlabel{ssub:chronische_toxizit_t}{{16.3}{105}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.3.1}Nitrosamine / Nitrosamide}{105}}
\newlabel{sub:nitrosamine_nitrosamide}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Exogene Enstehung}{105}}
\newlabel{ssub:subsubsection_name}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Endogene Entstehung}{105}}
\newlabel{ssub:endogene_entstehung}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkung}{105}}
\newlabel{ssub:wirkung}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Toxizit\IeC {\"a}t}{105}}
\newlabel{ssub:akute_toxizit_t}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Andere krebserzeugende Substanzen}{105}}
\newlabel{ssub:andere_krebserzeugende_substanzen_aromatische_amine_gegrilltes_fleisch_tabakrauch_aflatoxine_metalle_ni_cr_as_}{{16.3.1}{105}}
\@writefile{toc}{\contentsline {section}{\numberline {16.4}Pilzgifte}{105}}
\newlabel{sec:pilzgifte}{{16.4}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Niedere Pilze (Ascomyceten)}{105}}
\newlabel{ssub:niedere_pilze_ascomyceten_}{{16.4}{105}}
\@writefile{toc}{\contentsline {subsubsection}{H\IeC {\"o}here Pilze (Basidiomyceten)}{105}}
\newlabel{ssub:h_here_pilze_basidiomyceten_}{{16.4}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Fliegenpilz (Amanita muscaria); Pantherpilz (Amanita pantherina)}{105}}
\newlabel{ssub:subsubsection_name}{{16.4}{105}}
\@writefile{toc}{\contentsline {subsubsection}{Risspilze (Inocybe \IeC {\textendash } Arten)}{105}}
\newlabel{ssub:risspilze_inocybe_arten_}{{16.4}{105}}
\@writefile{toc}{\contentsline {section}{\numberline {16.5}Chemische Kampfstoffe}{106}}
\newlabel{sec:chemische_kampfstoffe}{{16.5}{106}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.5.1}Organophosphate}{106}}
\newlabel{sub:organophosphate}{{16.5.1}{106}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.5.2}Alkylatien}{106}}
\newlabel{sub:alkylatien}{{16.5.2}{106}}
\@writefile{toc}{\contentsline {subsubsection}{Symptomatik}{106}}
\newlabel{ssub:symptomatik}{{16.5.2}{106}}
\@writefile{toc}{\contentsline {subsubsection}{Therapie}{106}}
\newlabel{ssub:therapie}{{16.5.2}{106}}
\@writefile{toc}{\contentsline {section}{\numberline {16.6}Wichtige Intoxikationen}{106}}
\newlabel{sec:wichtige_intoxikationen}{{16.6}{106}}
\@writefile{toc}{\contentsline {subsection}{\numberline {16.6.1}Typische Vergiftungssyndrome}{107}}
\newlabel{sub:typische_vergiftungssyndrome}{{16.6.1}{107}}
\@writefile{toc}{\contentsline {chapter}{\numberline {17}Antiinfektiva}{108}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiinfektiva}{{17}{108}}
\@writefile{toc}{\contentsline {section}{\numberline {17.1}Antibakterielle Wirkstoffe}{108}}
\newlabel{sec:antibakterielle_wirkstoffe}{{17.1}{108}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.1}Definitionen}{108}}
\newlabel{sub:definitonen}{{17.1.1}{108}}
\newlabel{par:chemotherapeutika}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{Chemotherapeutika}{108}}
\newlabel{par:antibiotika}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{Antibiotika}{108}}
\newlabel{par:bakteriostase}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{Bakteriostase}{108}}
\newlabel{par:bakterizidie}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{Bakterizidie}{108}}
\newlabel{par:mhk_mic_minimale_hemmkonzentration}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{MHK (MIC) - minimale Hemmkonzentration}{108}}
\newlabel{par:mbk_mbc_minimale_bakterizide_konzentration}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{MBK (MBC) - minimale bakterizide Konzentration}{108}}
\newlabel{par:pae_postantibiotischer_effekt}{{17.1.1}{108}}
\@writefile{toc}{\contentsline {paragraph}{PAE - Postantibiotischer Effekt}{108}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.2}Hemmstoffe der Tretrahdrofols\IeC {\"a}ure-Synthese}{108}}
\newlabel{sub:hemmstoffe_der_tretrahdrofols_ure_synthese}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Sufonamide (Sulfamethoxazol)}{108}}
\newlabel{ssub:sufonamide_sulfamethoxazol_}{{17.1.2}{108}}
\newlabel{par:wirkmechanismus}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{108}}
\newlabel{par:nebenwirkungen}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {paragraph}{Nebenwirkungen}{108}}
\@writefile{toc}{\contentsline {subsubsection}{Diaminopyridine Trimethoprim}{108}}
\newlabel{ssub:diaminopyridine}{{17.1.2}{108}}
\newlabel{par:wirkmechanismus}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{108}}
\newlabel{par:nebenwirkungen}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {paragraph}{Nebenwirkungen}{108}}
\newlabel{par:indikationen}{{17.1.2}{108}}
\@writefile{toc}{\contentsline {paragraph}{Indikationen}{108}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.3}Hemmstoffe der bakteriellen Zellwandsynthese}{108}}
\newlabel{sub:hemmstoffe_der_bakteriellen_zellwandsynthese}{{17.1.3}{108}}
\@writefile{toc}{\contentsline {subsubsection}{$\beta $-Lactame: Penicilline, Cephalosporine, atypische Laktame}{109}}
\newlabel{ssub:subsubsection_name}{{17.1.3}{109}}
\newlabel{par:wirkmechanismus}{{17.1.3}{109}}
\@writefile{toc}{\contentsline {paragraph}{Wirkmechanismus}{109}}
\@writefile{toc}{\contentsline {subsubsection}{Benzylpenicilline}{109}}
\newlabel{ssub:benzylpenicilline}{{17.1.3}{109}}
\@writefile{toc}{\contentsline {subsubsection}{Oral-Penicilline}{109}}
\newlabel{ssub:oral_penicilline}{{17.1.3}{109}}
\newlabel{par:vorteile}{{17.1.3}{109}}
\@writefile{toc}{\contentsline {paragraph}{Vorteile}{109}}
\@writefile{toc}{\contentsline {subsubsection}{Isoazolyl-Penicilline}{109}}
\newlabel{ssub:isoazolyl_penicilline}{{17.1.3}{109}}
\@writefile{toc}{\contentsline {subsubsection}{Amiopenicilline}{110}}
\newlabel{ssub:amiopenicilline}{{17.1.3}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Penicilline mit erweitertem Spektrum (Gram -)}{110}}
\newlabel{par:acylaminopenicilline}{{17.1.3}{110}}
\@writefile{toc}{\contentsline {paragraph}{Acylaminopenicilline}{110}}
\newlabel{par:paragraph_name}{{17.1.3}{110}}
\@writefile{toc}{\contentsline {paragraph}{$\beta $-Lactamasehemmer}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Cephalosporine}{110}}
\newlabel{ssub:cephalosporine}{{17.1.3}{110}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.4}Hemmstoffe der bakteriellen Proteinsynthese}{110}}
\newlabel{sub:hemmstoffe_der_bakteriellen_proteinsynthese}{{17.1.4}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Aminoglykoside}{110}}
\newlabel{ssub:aminoglykoside}{{17.1.4}{110}}
\@writefile{toc}{\contentsline {subsubsection}{Tetracycline}{111}}
\newlabel{ssub:tetracycline}{{17.1.4}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Glycycycline}{111}}
\newlabel{ssub:glycycycline}{{17.1.4}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Makrolide}{111}}
\newlabel{ssub:makrolide}{{17.1.4}{111}}
\@writefile{toc}{\contentsline {subsubsection}{Chinolone - Gyrasehemmer}{111}}
\newlabel{ssub:chinolone_gyrasehemmer}{{17.1.4}{111}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.5}Resistenzmechanismen}{112}}
\newlabel{sub:subsection_name}{{17.1.5}{112}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.1.6}Reserve-Antibiotika}{112}}
\newlabel{sub:reserve_antibiotika}{{17.1.6}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Mit sehr breitem Spektrum}{112}}
\newlabel{ssub:mit_sehr_breitem_spektrum}{{17.1.6}{112}}
\@writefile{toc}{\contentsline {subsubsection}{Mit sehr selektivem Spektrum}{113}}
\newlabel{ssub:mit_sehr_selektivem_spektrum}{{17.1.6}{113}}
\@writefile{toc}{\contentsline {section}{\numberline {17.2}Tuberkulosemittel}{113}}
\newlabel{sec:tuberkulosemittel}{{17.2}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.2.1}Kurzzeittherapie}{113}}
\newlabel{sub:kurzzeittherapie}{{17.2.1}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.2.2}Langzeittherapie}{113}}
\newlabel{sub:langzeittherapie}{{17.2.2}{113}}
\@writefile{toc}{\contentsline {section}{\numberline {17.3}Antimykotika}{113}}
\newlabel{sec:antimykotika}{{17.3}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.1}Allylamine (Squalenepoxidase-Hemmer)}{113}}
\newlabel{sub:allylamine_squalenepoxidase_hemmer_}{{17.3.1}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.2}Azol-Antimykotika (Lanosterin-Demethylase-Hemmer)}{113}}
\newlabel{sub:azol_antimykotika_lanosterin_demethylase_hemmer_}{{17.3.2}{113}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.3.3}Polyen-Antimykotika}{114}}
\newlabel{sub:polyen_antimykotika}{{17.3.3}{114}}
\@writefile{toc}{\contentsline {section}{\numberline {17.4}Prophylaxe und Therapie der Malaria}{114}}
\newlabel{sec:prophylaxe_und_therapie_der_malaria}{{17.4}{114}}
\@writefile{toc}{\contentsline {section}{\numberline {17.5}Virustatika}{114}}
\newlabel{sec:virustatika}{{17.5}{114}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.5.1}Antimetabolite}{114}}
\newlabel{sub:antimetabolite}{{17.5.1}{114}}
\@writefile{toc}{\contentsline {subsection}{\numberline {17.5.2}Antiretrovirale Therapie}{115}}
\newlabel{sub:antiretrovirale_therapie}{{17.5.2}{115}}
\@writefile{toc}{\contentsline {subsubsection}{Beispiel Initialtherapie bei HIV}{115}}
\newlabel{ssub:beispiel_initialtherapie_bei_hiv}{{17.5.2}{115}}
\newlabel{par:mimbranfusionshemmer}{{17.5.2}{115}}
\@writefile{toc}{\contentsline {paragraph}{Mimbranfusionshemmer}{115}}
\newlabel{par:neuramidasehemmer}{{17.5.2}{115}}
\@writefile{toc}{\contentsline {paragraph}{Neuramidasehemmer}{115}}
\@writefile{toc}{\contentsline {chapter}{\numberline {18}Hypnotika}{116}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:hypnotika}{{18}{116}}
\@writefile{toc}{\contentsline {section}{\numberline {18.1}$\gamma $-Aminobutters\IeC {\"a}ure (GABA)}{116}}
\newlabel{sec:section_name}{{18.1}{116}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.1.1}GABA-Rezeptoren}{116}}
\newlabel{sub:gaba_rezeptoren}{{18.1.1}{116}}
\@writefile{toc}{\contentsline {subsubsection}{GABA$_A-Rezeptor$}{116}}
\newlabel{ssub:gaba__a_}{{18.1.1}{116}}
\@writefile{toc}{\contentsline {subsubsection}{GABA$_B$-Rezeptor}{116}}
\newlabel{ssub:gaba__b_rezeptor}{{18.1.1}{116}}
\@writefile{toc}{\contentsline {section}{\numberline {18.2}Benzodiazipine}{117}}
\newlabel{sec:benzodiazipine}{{18.2}{117}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkprofil}{117}}
\newlabel{ssub:wirkprofil}{{18.2}{117}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{117}}
\newlabel{ssub:pharmakokinetik}{{18.2}{117}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{117}}
\newlabel{ssub:unerw_nschte_wirkungen}{{18.2}{117}}
\@writefile{toc}{\contentsline {subsubsection}{Abh\IeC {\"a}ngigkeit und Toleranz}{117}}
\newlabel{ssub:abh_ngigkeit_und_toleranz}{{18.2}{117}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{118}}
\newlabel{ssub:akute_vergiftung}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{118}}
\newlabel{ssub:wechselwirkungen}{{18.2}{118}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.2.1}Zyklopyrrolone (Zopiclon); Imidazopyridine (Zolpidem); Pyrazolopyrimidine (Zaleplon)}{118}}
\newlabel{sub:zyklopyrrolone_zopiclon_imidazopyridine_zolpidem_pyrazolopyrimidine_zaleplon_}{{18.2.1}{118}}
\@writefile{toc}{\contentsline {section}{\numberline {18.3}Behandlung von Schlafst\IeC {\"o}rungen}{118}}
\newlabel{sec:behandlung_von_schlafst_rungen}{{18.3}{118}}
\@writefile{toc}{\contentsline {subsubsection}{\IeC {\quotedblbase }Vier-K-Regel\IeC {\textquotedblleft } (nach Borb\IeC {\'e}ly, 1986)}{118}}
\newlabel{ssub:_vier_k_regel_nach_borb_ly_1986_}{{18.3}{118}}
\@writefile{toc}{\contentsline {subsection}{\numberline {18.3.1}Empfehlungen der Deutschen Gesellschaft f\IeC {\"u}r Schlafforschung und Schlafmedizin zur Anwendung von Benzodiazepinen}{118}}
\newlabel{sub:subsection_name}{{18.3.1}{118}}
\@writefile{toc}{\contentsline {chapter}{\numberline {19}Narkotika}{119}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:narkotika}{{19}{119}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{119}}
\newlabel{ssub:wirkmechanismus}{{19}{119}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.2}Inhalationsnarkotika}{119}}
\newlabel{sub:inhalationsnarkotika}{{19.0.2}{119}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{119}}
\newlabel{ssub:pharmakokinetik}{{19.0.2}{119}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.3}Isofluran, Desfluran, Sevofluran}{120}}
\newlabel{sub:isofluran_desfluran_sevofluran}{{19.0.3}{120}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.0.4}Lachgas / N$_2$O / Stickoxydul}{120}}
\newlabel{sub:lachgas_n__2_o_stickoxydul}{{19.0.4}{120}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{120}}
\newlabel{ssub:wirkmechanismus}{{19.0.4}{120}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{120}}
\newlabel{ssub:unerw_nschte_wirkungen}{{19.0.4}{120}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{120}}
\newlabel{ssub:einsatz}{{19.0.4}{120}}
\@writefile{toc}{\contentsline {section}{\numberline {19.1}Injektionsnarkotika}{120}}
\newlabel{sec:injektionsnarkotika}{{19.1}{120}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.1}Barbiturate}{121}}
\newlabel{sub:barbiturate}{{19.1.1}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.2}Ketamin}{121}}
\newlabel{sub:ketamin}{{19.1.2}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.3}Etomidat}{121}}
\newlabel{ssub:etomidat}{{19.1.3}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.4}Propofol}{121}}
\newlabel{sub:propofol}{{19.1.4}{121}}
\@writefile{toc}{\contentsline {subsection}{\numberline {19.1.5}Benzodiazepine}{121}}
\newlabel{sub:benzodiazepine}{{19.1.5}{121}}
\@writefile{toc}{\contentsline {section}{\numberline {19.2}Kombinationsnarkose (Beispiel)}{122}}
\newlabel{sec:kombinationsnarkose_}{{19.2}{122}}
\@writefile{toc}{\contentsline {subsubsection}{Pr\IeC {\"a}medikation}{122}}
\newlabel{ssub:pr_medikation}{{19.2}{122}}
\@writefile{toc}{\contentsline {subsubsection}{Einleitung}{122}}
\newlabel{ssub:einleitung}{{19.2}{122}}
\@writefile{toc}{\contentsline {subsubsection}{Ausleitung}{122}}
\newlabel{ssub:ausleitung}{{19.2}{122}}
\@writefile{toc}{\contentsline {chapter}{\numberline {20}Anti-Parkinsonmittel}{123}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:anti_parkinsonmittel}{{20}{123}}
\@writefile{toc}{\contentsline {section}{\numberline {20.1}Dopaminerges System}{123}}
\newlabel{sec:dopaminerges_system}{{20.1}{123}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.1.1}Dopaminerge Synapse}{123}}
\newlabel{sub:dopaminerge_synapse}{{20.1.1}{123}}
\newlabel{par:dopaminerge_rezeptoren}{{20.1.1}{123}}
\@writefile{toc}{\contentsline {paragraph}{Dopaminerge Rezeptoren}{123}}
\newlabel{par:dopaminerge_systeme}{{20.1.1}{123}}
\@writefile{toc}{\contentsline {paragraph}{Dopaminerge Systeme}{123}}
\@writefile{toc}{\contentsline {section}{\numberline {20.2}Morbus Parkinson}{123}}
\newlabel{sec:morbus_parkinson}{{20.2}{123}}
\@writefile{toc}{\contentsline {section}{\numberline {20.3}Extrapyramidales System / Basalganglien}{123}}
\newlabel{sec:extrapyramidales_system_basalganglien}{{20.3}{123}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.1}Funktionskreis}{123}}
\newlabel{sub:funktionskreis}{{20.3.1}{123}}
\@writefile{toc}{\contentsline {subsubsection}{Thalamus \IeC {\textendash } Cortex \IeC {\textendash } Basalganglien}{123}}
\newlabel{ssub:subsubsection_name}{{20.3.1}{123}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.2}Direkter Weg}{124}}
\newlabel{sub:ditekter_weg}{{20.3.2}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Striatum $\rightarrow $ Globus pallidus med. $\rightarrow $ Thalamus }{124}}
\newlabel{ssub:subsubsection_name}{{20.3.2}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Indirekter Weg: Striatum $\rightarrow $ Globus pallidus lat. $\rightarrow $ Ncl. Subthalam. $\rightarrow $ Thalamus}{124}}
\newlabel{ssub:indirekter_weg_striatum_globus_pallidus_lat_ncl_subthalam_thalamus}{{20.3.2}{124}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.3.3}Bei M.Parkinson}{124}}
\newlabel{sub:bei_m_parkinson}{{20.3.3}{124}}
\@writefile{toc}{\contentsline {section}{\numberline {20.4}Therapie des Morbus Parkinson}{124}}
\newlabel{sec:therapie_des_morbus_parkinson}{{20.4}{124}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.1}Erh\IeC {\"o}hung der striatalen Dopaminkonz. durch Gabe von L-Dopa sowie d. Hemmung des Dopaminabbaus (MAO$_B$/COMT-Hemmer)}{124}}
\newlabel{sub:erh_hung_der_striatalen_dopaminkonz_durch_gabe_von_l_dopa_sowie_d_hemmung_des_dopaminabbaus_mao__b_comt_hemmer_}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Levodopa (L-Dopa)}{124}}
\newlabel{ssub:levodopa_}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Dopa-Decarboxylase-Hemmer}{124}}
\newlabel{ssub:dopa_decarboxylase_hemmer}{{20.4.1}{124}}
\newlabel{par:paragraph_name}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Wirkungseinschr\IeC {\"a}nkung}{124}}
\newlabel{par:paragraph_name}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Wirkungsfluktuation / on-off-Ph\IeC {\"a}nomen}{124}}
\newlabel{par:paragraph_name}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Dyskinesien}{124}}
\newlabel{par:paragraph_name}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{unerw. Wirkungen}{124}}
\newlabel{par:einsatz}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {paragraph}{Einsatz}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Monoaminoxidase B Hemmer}{124}}
\newlabel{ssub:monoaminoxidase_b_hemmer}{{20.4.1}{124}}
\@writefile{toc}{\contentsline {subsubsection}{Catecho-O-Methyltransferase(COMT)-Hemmer}{125}}
\newlabel{ssub:catecho_o_methyltransferase_}{{20.4.1}{125}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.2}Direkte Stimulation zentraler Dopaminrezeptoren}{125}}
\newlabel{sub:direkte_stimulation_zentraler_dopaminrezeptoren}{{20.4.2}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Dopamin-Rezeptoragonisten}{125}}
\newlabel{ssub:dopamin_rezeptoragonisten}{{20.4.2}{125}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.3}Hemmung zentraler muscarinischer Rezeptoren}{125}}
\newlabel{sub:hemmung_zentraler_muscarinischer_rezeptoren}{{20.4.3}{125}}
\@writefile{toc}{\contentsline {subsubsection}{Muskarinrezeptor-Antagonisten}{125}}
\newlabel{ssub:muskarinrezeptor_antagonisten}{{20.4.3}{125}}
\@writefile{toc}{\contentsline {subsection}{\numberline {20.4.4}Blockade von Glutamat-Rezepotoren (NMDA-Typ)}{125}}
\newlabel{sub:blockade_von_glutamat_rezepotoren_}{{20.4.4}{125}}
\@writefile{toc}{\contentsline {subsubsection}{NMDA Rezeptor-Antagonisten}{125}}
\newlabel{ssub:nmda_rezeptor_antagonisten}{{20.4.4}{125}}
\@writefile{toc}{\contentsline {chapter}{\numberline {21}Antiepileptika}{126}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antiepileptika}{{21}{126}}
\@writefile{toc}{\contentsline {section}{\numberline {21.1}Formen der Epilepsie}{126}}
\newlabel{sec:formen_der_epilepsie}{{21.1}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.1}Fokal}{126}}
\newlabel{sub:fokal}{{21.1.1}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.2}Pim\IeC {\"a}r generalisiert}{126}}
\newlabel{sub:pim_r_generalisiert}{{21.1.2}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.1.3}Nicht klassifizierbar}{126}}
\newlabel{sub:nicht_klassifizierbar}{{21.1.3}{126}}
\@writefile{toc}{\contentsline {section}{\numberline {21.2}Pathomechanismen der Epilepsie}{126}}
\newlabel{sec:pathomechanismen_der_epilepsie}{{21.2}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.2.1}Zellul\IeC {\"a}res Korrelat}{126}}
\newlabel{sub:zellul_res_korrelat}{{21.2.1}{126}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.2.2}Versagen der Umfeldhemmung}{126}}
\newlabel{sub:versagen_der_umfeldhemmung}{{21.2.2}{126}}
\@writefile{toc}{\contentsline {section}{\numberline {21.3}Antiepileptika}{127}}
\newlabel{sec:antiepileptika}{{21.3}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.1}Hemmung der Erregbarkeit von Neuronen}{127}}
\newlabel{sub:hemmung_der_erregbarkeit_von_neuronen}{{21.3.1}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.2}Verst\IeC {\"a}rkung der Umfeldhemmung epileptisch aktiver Neurone}{127}}
\newlabel{sub:verst_rkung_der_umfeldhemmung_epileptisch_aktiver_neurone}{{21.3.2}{127}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.3}Pharmaka}{127}}
\newlabel{sub:pharmaka}{{21.3.3}{127}}
\@writefile{toc}{\contentsline {subsubsection}{Pheytoin}{127}}
\newlabel{ssub:pheytoin}{{21.3.3}{127}}
\@writefile{toc}{\contentsline {subsubsection}{Carbamazepin}{127}}
\newlabel{ssub:carbamazepin}{{21.3.3}{127}}
\@writefile{toc}{\contentsline {subsubsection}{Lamotrigin}{127}}
\newlabel{ssub:lamotrigin}{{21.3.3}{127}}
\@writefile{toc}{\contentsline {subsubsection}{Valproins\IeC {\"a}ure}{127}}
\newlabel{ssub:valproins_ure}{{21.3.3}{127}}
\@writefile{toc}{\contentsline {subsubsection}{Ethosuximid}{128}}
\newlabel{ssub:ethosuximid}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Gabapentin}{128}}
\newlabel{ssub:gabapentin}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Levetiracetam}{128}}
\newlabel{ssub:levetiracetam}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Benzodiazepine}{128}}
\newlabel{ssub:benzodiazepine}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Phenobarbital, Primidon}{128}}
\newlabel{ssub:phenobarbital_primidon}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Vigabatrin}{128}}
\newlabel{ssub:vigabatrin}{{21.3.3}{128}}
\@writefile{toc}{\contentsline {subsection}{\numberline {21.3.4}Antiepileptika - Indikationen}{128}}
\newlabel{sub:antiepileptika_indikationen}{{21.3.4}{128}}
\@writefile{toc}{\contentsline {section}{\numberline {21.4}Pharmakotherapie bei Status epilepticus}{128}}
\newlabel{sec:pharmakotherapie_bei_status_epilepticus}{{21.4}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Diazepam}{128}}
\newlabel{ssub:diazepam}{{21.4}{128}}
\@writefile{toc}{\contentsline {subsubsection}{Phenytoin}{129}}
\newlabel{ssub:phenytoin}{{21.4}{129}}
\@writefile{toc}{\contentsline {chapter}{\numberline {22}Antidepressiva}{130}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:antidepressiva}{{22}{130}}
\@writefile{toc}{\contentsline {section}{\numberline {22.1}Pharmakodynamik}{130}}
\newlabel{sec:pharmakodynamik}{{22.1}{130}}
\@writefile{toc}{\contentsline {paragraph}{Nicht-Selektive Monoamin-R\IeC {\"u}ckaufnahme-Hemmer (NSMRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Serotonin/Noradrenalin-R\IeC {\"u}ckaufnahme-Hemmer (SSNRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Serotonin-R\IeC {\"u}ckaufnahme-Hemmer (SSRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{Selektive Noradrenalin-R\IeC {\"u}ckaufnahme-Hemmer (SNRI)}{130}}
\@writefile{toc}{\contentsline {paragraph}{$\alpha _2$-Adrenozeptor-Antagonisten}{130}}
\@writefile{toc}{\contentsline {paragraph}{Monoamin-Oxidase-Hemmer (MAO-Hemmer)}{131}}
\@writefile{toc}{\contentsline {section}{\numberline {22.2}Nicht-selektive Monoamin-\IeC {\quotedblbase }Reuptake\IeC {\textquotedblleft }-Inhibitoren (NSMRI)}{131}}
\newlabel{sec:nicht_selektive_monoamin_reuptake_inhibitoren_nsmri_}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{131}}
\newlabel{ssub:pharmakokinetik}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{unerw\IeC {\"u}nschte Wirkungen}{131}}
\newlabel{ssub:subsubsection_name}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Interaktionen}{131}}
\newlabel{ssub:interaktionen}{{22.2}{131}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{131}}
\newlabel{ssub:akute_vergiftung}{{22.2}{131}}
\@writefile{toc}{\contentsline {section}{\numberline {22.3}Selektive Serotonin-\IeC {\quotedblbase }Reuptake\IeC {\textquotedblleft }-Inhibitoren (SSRI)}{131}}
\newlabel{sec:selektive_serotonin_reuptake_inhibitoren_ssri_}{{22.3}{131}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{132}}
\newlabel{ssub:pharmakokinetik}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{132}}
\newlabel{ssub:unerw_nschte_wirkungen}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{132}}
\newlabel{sub:akute_vergiftung}{{22.3}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{132}}
\newlabel{ssub:wechselwirkungen}{{22.3}{132}}
\@writefile{toc}{\contentsline {section}{\numberline {22.4}MAO-A-Hemer}{132}}
\newlabel{sec:mao_a_hemer}{{22.4}{132}}
\@writefile{toc}{\contentsline {section}{\numberline {22.5}Pharmaka zur Phasenprophylaxe affektiver Psychosen bzw. Therapie einer Manie}{132}}
\newlabel{sec:pharmaka_zur_phasenprophylaxe_affektiver_psychosen_bzw_therapie_einer_manie}{{22.5}{132}}
\@writefile{toc}{\contentsline {subsection}{\numberline {22.5.1}Lithium}{132}}
\newlabel{sub:lithium}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Einsatz}{132}}
\newlabel{ssub:einsatz}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Wirkmechanismus}{132}}
\newlabel{ssub:wirkmechanismus}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{132}}
\newlabel{ssub:pharmakokinetik}{{22.5.1}{132}}
\@writefile{toc}{\contentsline {subsubsection}{Unerw\IeC {\"u}nschte Wirkungen}{133}}
\newlabel{ssub:unerw_nschte_wirkungen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{akute Vergiftung}{133}}
\newlabel{ssub:akute_vergiftung}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Problem}{133}}
\newlabel{ssub:problem}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{133}}
\newlabel{ssub:wechselwirkungen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {subsubsection}{Kontraindikationen}{133}}
\newlabel{ssub:kontraindikationen}{{22.5.1}{133}}
\@writefile{toc}{\contentsline {chapter}{\numberline {23}Neuroleptika}{134}}
\@writefile{lof}{\addvspace {10\p@ }}
\@writefile{lot}{\addvspace {10\p@ }}
\newlabel{cha:neuroleptika}{{23}{134}}
\@writefile{toc}{\contentsline {section}{\numberline {23.1}"Klassiche" Neuroleptika}{134}}
\newlabel{sec:}{{23.1}{134}}
\@writefile{toc}{\contentsline {section}{\numberline {23.2}Wirkmechanismen / Nebenwirkungen klassischer Neuroleptika}{134}}
\newlabel{sec:wirkmechanismen_nebenwirkungen_klassischer_neuroleptika}{{23.2}{134}}
\@writefile{toc}{\contentsline {subsubsection}{Pharmakokinetik}{135}}
\newlabel{ssub:pharmakokinetik}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Wechselwirkungen}{135}}
\newlabel{ssub:wechselwirkungen}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Indikationen}{135}}
\newlabel{ssub:indikationen}{{23.2}{135}}
\@writefile{toc}{\contentsline {subsubsection}{Neuroleptikavergiftung}{136}}
\newlabel{ssub:neuroleptikavergiftung}{{23.2}{136}}
\@writefile{toc}{\contentsline {section}{\numberline {23.3}"Atypische" Neuroleptika}{136}}
\newlabel{sec:section_name}{{23.3}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.1}Neuroleptika mit anderem Wirkprofil}{136}}
\newlabel{sub:neuroleptika_mit_anderem_wirkprofil}{{23.3.1}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.2}Antagonismus am Serotonien 5-HT$_{2A}$ Rezeptor}{136}}
\newlabel{sub:antagonismus_am_serotonien_5_ht__}{{23.3.2}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.3}Nebenwirkungen}{136}}
\newlabel{sub:nebenwirkungen}{{23.3.3}{136}}
\@writefile{toc}{\contentsline {subsection}{\numberline {23.3.4}Rezeptorprofil atyptischer Neuroleptika (Antagonismus)}{136}}
\newlabel{sub:rezeptorprofil_atyptischer_neuroleptika_}{{23.3.4}{136}}
